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Abstract 
Von Hippel-Lindau (VHL) disease is a dominantly inherited cancer syndrome 
characterized by the development of multiple tumours, among which the most common are 
tumours of blood vessels called hemangioblastomas (HB) that can be found in the retina 
and the central nervous system (CNS). The disease is caused by germline mutations in the 
VHL tumour suppressor gene and tumour development is linked to somatic inactivation of 
the remaining wild-type allele.  
The best documented role of pVHL is as the substrate recognition component of a 
Skp1/cullin/F-box (SCF)-like E3 ubiquitin protein ligase complex that ubiquitinates the 
oxygen-sensitive α-subunit of hypoxia inducible factors HIF-1 and HIF-2 under normoxia 
and targets them for proteasomal degradation, thereby inactivating HIF. Loss of VHL 
function leads to the constitutive activation of HIF and subsequent up-regulation of 
hypoxia-inducible mRNAs encoding angiogenic growth factors such as vascular 
endothelial growth factor (VEGF), Erythropoietin (EPO) and glucose transporter 1 
(GLUT1). Up-regulation of these factors characterizes VHL-associated tumours at the 
molecular level.  
VHL gene expression studies on human fetal and adult tissues showed VHL mRNA 
to be ubiquitously detectable. Expression was not restricted to specific areas known to 
undergo abnormal differentiation as part of the VHL syndrome such as kidney, cerebellum 
and pancreas, but it was also present, among others, in the heart, lung and prostate. In 
addition VHL gene expression was evident in all derivatives of the three germ cell layers 
also during mouse embryogenesis, being most prominent in epithelial components of the 
lung, kidney and eye. 
Expression studies of the VHL protein (pVHL) utilizing poly- and monoclonal 
antibodies against human VHL revealed wide cytoplasmic expression in human adult 
tissues. However, little is known about VHL expression patterns during development and 
in particular, the detailed distribution of VHL within specific tissues.   
To investigate pVHL expression during murine development and adulthood a 
mouse pVHL-specific antibody was raised and utilized in a detailed immunohistochemical 
study focusing on the development of two tissues that play a very important role in the 
course of VHL disease, namely the retina and cerebellum. 
Studying VHL disease, as any other disease, in humans is a difficult task that can be 
circumvented by the usage of genetically engineered mice that phenotypically mimic the 
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disease. The complete knockout of VHL unfortunately didn’t provide a mouse model in 
which to investigate molecular pathology, gene-gene or protein-tissue interactions or even 
therapeutic intervention as the animals died early during gestation.  In an attempt to create 
a mouse model that circumvented the block encountered in the complete knockout, we used 
Cre/loxP technology to design a strategy for creating a conditional VHL knockout, i.e. 
mice having exon 1 flanked by loxP sites (floxed). As our intent was not crowned with 
success and the floxed VHL mice were published in the meantime by another laboratory 
we could benefit by using these mice to specifically knock-out VHL in tissues we found to 
be interesting due to expression studies that had been undertaken as part of this thesis.  
In the thesis presented herein the expression of pVHL in the retina and the 
cerebellum is described and the potential value of localizing VHL to previously 
unidentified cells is discussed (chapter 8). Moreover, an outline of an unsuccessful 
endeavour to create a conditional knockout is provided (chapter 7). Nevertheless, given the 
availability of such mice from a different laboratory, we undertook a cell-specific deletion 
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Abbreviations  
APMO adnexal papillary cystadenoma of probable mesonephric origin 
ARNT    aryl hydrocarbon receptor nuclear translocator 
BAC    bacterial artificial chromosome 
BCS    bovine calf serum 
bp    base pair 
BrdU    5-Bromo-2'-deoxyuridine 
cDNA    complementary desoxyribonucleic acid 
CDK    cyclin-dependent kinase 
CDKI    cdk inhibitor 
Ci    curie 
CNS    central nervous system 
CRALBP   cellular retinaldehyde-binding protein 
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C-TAD    C-terminal transactivation domain 
Cul    cullin 
CT    C-terminal 
DAPI     4’6’-Diamidine-2’-Phenylindole Dihydrochloride 
DMEM     Dulbecco´s modified Eagle´s Medium 
DMSO     dimethylsulfoxide  
DNA    deoxyribonucleic acid 
DT-A    Diphtheria toxin A 
DTT    dithiothreitol 
dNTP    desoxyribonucleoside-triphosphate 
ECL    enhanced chemi-luminescence 
EDTA    ethylenediamine tetra-acetic acid 
EGL    external granular (germinal) layer 
ELST    endolymphatic sac tumour 
EPAS    endothelial PAS domain protein 
EPO    erythropoietin 
ES cells    embryonic stem cells 
EtOH    ethanol 
FCS    fetal calf serum 
FIH    factor inhibiting HIF 
FITC    Fluorescein 
FRT    Flp recombinase target 
G418    geneticin 
GABA    γ-aminobutyric acid 
GCL    ganglion cell layer 
GFAP    glial fibrillary acidic protein 
GL    granular layer 
HB    hemangioblastoma 
HBSS Hank’s balanced salt solution 
HEPES  N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
HIF hypoxia inducible factor 
H2O    water 
HRE    hypoxia responsive element 
HSV    herplex simplex virus 
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INL    inner nuclear layer 
KAc    potassium acetate 
kb    kilo-base (i.e. 1000 nucleotides) 
KCl    potassium chloride 
kD    kilo-dalton 
KLH    keyhole limpet haemocyanin 
LB    Luria Bertami medium 
LIF    leukaemia inhibitory factor 
loxP    locus of crossover (x) in P1 
M    molar 
m    milli (10-3) 
µ micro (10-6) 
MEF    mouse embryo fibroblast 
MgCl2    magnesium chloride 
ML    molecular layer 
MMP    matrix metalloproteinase  
mRNA    messenger ribonucleic acid 
NaAc    sodium acetate 
NaCl    sodium chloride 
Na2HPO4   sodium hydrogen phosphate  
NaH2PO4   sodium dihydrogen orthophosphate 
NaOH    sodium hydroxide 
Neo    neomycin 
NGS    normal goat serum 
NT    N-terminal 
N-TAD    N-terminal transactivation domain 
OD    optical density 
ODD    oxygen-dependent degradation domain 
ONL    outer nuclear layer 
PBS    phosphate-buffered saline 
PCE    papillary cystadenomas of the epididymis 
PCR    polymerase chain reaction 
PDGF    platelet-derived growth factor 
Pheo    pheochromocytoma 
PMSF     phenyl-methyl-sulphonyl-fluoride 
RCC    renal cell carcinoma 
RT    room temperature 
RT-PCR    reverse transcriptase PCR  
SDS     sodium dodecyl sulfate 
TEMED    N,N,N’,N’-Tetramethylethylenediamine  
TGF    transforming growth factor 
TIMP    their tissue inhibitors of matrix metalloproteinases 
Tk    thymidine kinase 
Tris    Tris(hydroxymethyl)aminomethane (Tris base) 
U    unit of enzyme activity  
UTR    untranslated region 
VEGF    vascular endothelial growth factor 
VHL    von Hippel- Lindau 
WT    wild-type 
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 Chapter 1 
 
Von Hippel-Lindau Disease 
 
Von Hippel-Lindau (VHL) disease is a dominantly inherited family cancer syndrome that 
predisposes affected individuals to a variety of tumours including those of blood vessels 
(hemangioblastomas; HB) of the retina and the central nervous system (CNS), clear-cell 
carcinomas of the kidney (RCC), adrenal gland tumours (pheochromocytomas), 
endolymphatic sac tumours (ELST), and epididymal and broad ligament cystadenomas 
(AMPO) (FIG.1) (Lonser, 2003; Kaelin, 2002; Singh, 2001). The disease results from germline 
mutations and subsequent biallelic inactivation of the VHL gene as a prerequisite for 
tumour formation and affects 1 in 36 000-45 500 live births (Kondo & Kaelin, 2001; Maher & 











                    Figure 1: Location of the principal neoplasms seen in VHL disease (Barry & Krek, 2004). 
 
 The VHL disease was named after Eugen von Hippel, a german ophthalmologist, 
who first described eye angiomas and the familial occurrence of these retinal blood vessel 
tumours in 1904 (von Hippel, 1904), and Arvid Lindau, a Swedish neuropathologist, who in 
1926 appreciated that these retinal lesions were a marker for a systemic disorder that also 
involved blood vessel tumours of the central nervous system (Lindau, 1927).  
At the molecular level VHL disease presents itself as autosomal (not limited to one 
sex) recessive as VHL kindreds have a single germline mutation in one (inherited by an 
affected parent) of the two VHL alleles (Crossey et al., 1994; Maher et al., 1990). Only the 
somatic loss or inactivation of the remaining wild-type VHL allele (through deletion, 
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mutation or silencing by promoter 
methylation) initiates tumour 
development in accordance with 
Knudson’s two-hit hypothesis of 
tumourigenesis (FIG. 2B) (Knudson, 
1971). Nevertheless, as this somatic 
event occurs at a very high frequency, 
resulting in a high penetrance of VHL 
disease (> 90 %), the VHL disease 
presents itself clinically as an 
autosomal dominant disorder. However, 
one has to keep in mind that in addition 
to the biallelic deletion of VHL 
following the already present germline 
mutation, only cells that are 
constituents of susceptible target organs 
(CNS, kidneys etc.) eventually develop 
tumours. 
Figure 2. Knudson’s two-hit hypothesis for
tumourigenesis involving a tumour suppressor gene
(TSG).  (A) Normal individuals require somatic inactivation
of both alleles of a TSG for tumour formation = “two hits”
(B) Individuals with an inherited inactivated allele only
require inactivation of the corresponding TSG allele for
tumour progression = “one hit” 
                    Adapted from Richards et al. 2001
In keeping with the Knudson 2-hit model, VHL gene inactivation has also been shown 
in some sporadic tumours of the same histological types as observed in VHL disease. VHL 
protein function is lost in 50-80% of sporadic cases of renal clear-cell carcinomas (Brieger et 
al., 1999; Gnarra et al., 1994), as well as in some sporadic cases of CNS hemangioblastomas 
(Lee et al., 1998). In these cases the first hit occurs as a result of somatic mutation or 
promoter hypermethylation and then requires a second somatic mutation to occur in order 
for tumours to arise (FIG. 2A) (Maher et al., 1990). 
 
1.1 Clinical manifestations of VHL disease  
 
VHL disease, unlike most other diseases, does not occur exclusively in one organ or at a 
particular age and has no single primary symptom. The age of onset is variable as it 
depends on the expression of the disease within an individual and within a family, but the 
disease normally achieves full penetrance by the age of 65. 
Among the large number of tumours that have been shown to be linked to VHL 
disease the most recurrent ones are retinal and CNS hemangioblastomas, RCC and to a 
much lesser extent pheochromocytomas (although the latter is used to classify the disease 
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subtypes as discussed under 1.2). In addition to these “main” features, multiple renal, 
pancreatic and epididymal cysts can occur and in up to ca. 10 % of patients pancreatic islet 
cell tumours and endolymphatic sac tumours (ELST) of the inner ear are found. While 
hemangioblastomas are normally benign cystic tumours (although they can still be a cause 
of considerable morbidity), RCC, pheochromocytoma and pancreatic islet cell tumours can 
all be malignant.  
The main causes of death in VHL disease have been metastases from renal cell 
carcinomas and neurological complications of CNS hemangioblastomas, though in recent 
years due to improved surveillance, earlier diagnosis and improved treatments, the 
prognosis has improved and complications related to these tumours have been reduced. 
The phenotypes of VHL disease will be shortly discussed below (for reviews see 




Hemangioblastomas are benign non-metastasising blood vessel tumours that consist of a 
mixture of so-called “stromal cells” and blood vessels (pericytes and endothelial cells) 
(FIG. 3). The origin of the stromal cells is still a 
matter of debate (see also discussion) but it has 
been shown that these are the neoplastic 
component (the tumour cells) as they have lost 
pVHL expression and function, overproducing 
HIF target gene products such as vascular 
endothelial growth factor (VEGF) and platelet-
derived growth factor B chain (PDGF-β), which 
are likely to support the proliferation of the 
endothelial cells and pericytes respectively, 
transforming growth factor- α (TGF−α) and 
erythropoietin (EPO). Retinal and central nervous system hemangioblastomas in VHL 
disease are histologically indistinguishable and are therefore both referred to as 
hemangioblastomas.  
Figure 3. Histopathology of hemangioblastomas
(HB). HBs consist of stromal cells and blood
vessel cells-pericytes and endothelial cells. In
VHL disease the blood vessel cells have been
shown to be VHL+/-, whereas the stromal cells are
VHL-/-. Due to the lack of VHL function the
stromal cells accumulate high levels of hypoxia-
inducible factor HIF-1α, which in turn leads to the
overproduction of a number for HIF target genes
such as TGF- α, EPO, VEGF and PDGF-β. TGF-
 α probably acts in an autocrine loop. 
                      Adapted from Kaelin, 2002
 
1.1.1.1 Retinal Hemangioblastomas 
 
Among the manifestation of VHL disease retinal hemangioblastomas (HB; also called 
angiomas) appear to be among the most common and earliest tumours, seen in as many as 
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Figure 4. Retinal angioma 
in VHL disease. 
41-60 % of VHL patients. These tumours arise normally in the capillary bed of the retina, 
in the vascular tissue between the arterioles and venules in the 
circulatory system (FIG. 4). When capillaries form angiomas in 
the retina they start out extremely small and difficult to 
detect/see due to the fact that they form mostly in the periphery 
or on/near the optic disc far away from the area of central vision. 
Retinal hemangioblastomas are frequently multiple and if 
untreated may produce retinal detachment and hemorrhage 
leading to blindness. Detected early though most retinal angiomas respond to laser therapy 
or cryotherapy (reviews by Singh et al., 2001; The VHL Handbook under www.vhl.org). 
 
1.1.1.2 Central nervous system hemangioblastomas 
 
The most common tumours in VHL disease affecting 60-80 % of all VHL patients are 
central nervous system hemangioblastomas (or hemangiomas). These blood vessel tumours 
of the brain and spinal cord are benign but a major source of morbidity. Many patients with 
VHL disease ultimately develop multiple CNS hemangioblastomas and the management of 
brain stem and spinal tumours is often difficult and thus CNS involvement remains an 
important cause of morbidity and mortality for VHL patients. 
The cerebellum is the most frequent site of central nervous system 
hemangioblastomas (57-60 % of patients) followed by the spinal cord (13-12 %) and brain 
stem sites. The mean age at onset of cerebellar hemangioblastomas in VHL disease is 
considerably younger than in sporadic cases.  
 
1.1.2 Renal Clear Cell Carcinomas and renal cysts 
 
Renal Cell Carcinoma (RCC) occurs in 24-47 % of patients with VHL disease and affects a 
majority of the individuals with VHL disease, if they live long enough. In addition, RCC in 
VHL disease tends to be associated with renal cysts adding up to increase the finding of a 
renal lesion to 60 %. Renal cell carcinomas are the major malignant neoplasm in VHL 
disease and mutations in the VHL gene are the primary cause of inherited renal cancer. 
Renal cysts are frequent although they rarely produce significant renal impairment, but 
they can give rise, over time, to RCC. 
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1.1.3 Pheochromocytomas 
 
Pheochromocytomas are benign tumours of the adrenal gland that arise from neural crest 
tissue and produce elevated levels of catecholamines (norepinephrine and epinephrine) 
(Koch et al., 2001). Pheochromocytomas are present in about 7-19 % of VHL disease patients 
and tend to be multiple or bilateral. Although this type of tumour is not that frequent 
overall, in some families pheochromocytomas are the major manifestation and this has 
contributed to the classification criteria of the VHL disease as discussed under 1.2. 
 
1.1.4 Pancreatic cysts and neoplasms 
 
Pancreatic lesions in VHL disease are usually classified as nonsecretory (cyst and 
cystadenoma) or secretory (islet cell tumour) (Neumann et al., 1991). Among these the 
pancreatic cyst is the most common pancreatic lesion observed in about 15-30 % of 
patients with VHL disease. 
  Islet cell tumours consist of nests of polygonal cells with vesicular nuclei and are 
mostly asymptomatic but lesions can grow rapidly, cause biliary obstruction and 
metastasise to the liver or more distantly to the bone. An association may exist between 
islet cell tumours of the pancreas and pheochromocytomas since ca. 20 % of the VHL 
families with a high prevalence of pheochromocytoma will also develop islet cell tumours 
whereas this tumour is rare in other VHL families. 
 
1.1.5 Endolymphatic sac tumours (ELST) 
 
Slow-growing low-grade papillary adenocarcinomas may occur in up to 11 % of patients 
and are often bilateral. ELST is a recently recognized feature of VHL disease and may be 
more common than previously thought (Manski et al., 1997).  
 
1.1.6 Epididymal and broad ligament cystadenoma 
 
Papillary cystadenomas (a benign tumour with multiple cysts inside it, having higher 
density than a normal cyst) of the epididymis (PCE) are seen in approximately 10-26 % of 
men with VHL disease (Choyke et al., 1997). (The epididymis is a small, coiled conduit, 
which lies behind the testicle, in the scrotum, on the path to the vas deferens, the vessel, 
which carries the sperm from the testicle to the prostate gland.) 
A corresponding tumour in women is the adnexal (adjoining) papillary 
cystadenoma of probable mesonephric origin (APMO) of the broad ligament near the 
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fallopian tube (the channel carrying eggs from the ovary to the uterus). The broad ligament 
lies in folds and creases on top of both ovaries and uterine tubes, connecting these 
structures to the larger body of the uterus. 
 
1.2 Clinical diagnosis and classification of VHL disease 
 
 The diagnostic criteria for VHL disease are based upon three elements: retinal capillary or 
CNS hemangioblastoma, visceral lesions and family history of similar lesions (Melmon & 
Rosen, 1964). Patients with a family history and a hemangioblastoma (retinal or CNS), 
pheochromocytoma or RCC are diagnosed with the disease. Those patients with no 
relevant family history must have at least two CNS hemangioblastomas and a visceral 
tumour (except epididymal and renal cysts as these are frequent in the general population) 
to meet the diagnostic criteria.  
VHL disease can be classified into two main types, depending on the risk of 
developing pheochromocytoma (Table 1): 
  Type 1 families have a greatly reduced risk of pheochromocytomas but can develop 
all the other tumour types whereas Type 2 families have pheochromocytomas but have 
either a low risk (2A) or high risk (2B) for renal cell carcinoma. Type 2C families have 
pheochromocytomas only with no other neoplastic findings of VHL. The correlation of 
specific mutations and therefore the genotype with a specific VHL phenotype will be 
further elucidated under 1.3.3. 
 
 
Type         Clinica
   HB 
Type 1 + 
Type 2A + 
Type 2B + 
Type 2C     − 
 
Table 1: Classification of VHL di
types. In the germline mutation exa
amino acid indicated after the residu
 
 
                   Classification of VHL disease
l characteristics                              Germline VHL mutation 
RCC    Pheo. 
+ −     Deletions and truncations 
− +     Missense e.g. Tyr98His 
+ +     Missense e.g. Arg167Trp 
− +     Missense e.g. Leu188Val sease types and the most frequently mutated residues connected to the different 
mples, the amino acid of the specific residue number has been exchanged with the 
e number.              Adapted from Richards, 2001 
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1.3 The VHL gene and protein function 
 
1.3.1 The human VHL gene 
 
In humans the VHL tumour suppressor gene is located on the short arm of chromosome 3 
(3p25-26) (Latif et al., 1993), covering less than 20 kb of genomic DNA and encoding a 4.7 
kb mRNA. Alternative splicing yields a small proportion of VHL mRNA that lacks exon 2 
(isoform II), which is predicted, if translated, to produce an in-frame deletion of 41 amino 
acids. The identification of VHL patients with germline deletions in exon 2 resulting in 
isoform II expression only, suggests though that this isoform is not encoding a fully 
functional gene product (Gnarra et al.; 1994).  
The VHL coding sequence is contained within 3 exons (exon 1= 70 bp 5’ UTR and 
340 bp coding sequence, exon 2= 123 bp coding sequence and exon 3= 179 bp coding 
sequence and 4 kb 3’ UTR) (FIG. 5a). 
Codons 14 to 53 encode eight copies 
of an acidic pentameric repeat [Gly-X-
Glu-Glu-X; (GXEEX)8] with 
homology to a procyclic surface 
membrane protein of Trypanosoma 
brucei. However the functional 
significance of this region is still 
unclear. The 642 nucleotides of the 
VHL gene encode a polypeptide of 213 amino acids with an apparent molecular weight of 
ca. 30 kDa and therefore termed pVHL30 (Iliopoulos et al., 1995). Due to alternative translation 
initiation at an internal methionine located at residue 54, a shorter VHL protein, pVHL19, 
of 160 amino acids and with an apparent molecular weight of 18-19 kDa is also 
synthesized (Blankenship et al., 1999; Schoenfeld et al., 1998; Iliopoulos et al., 1998) (FIG. 5b). This 
protein lacks the acidic domain. 
 
Figure 5. VHL gene (a) and protein (b) structure. 
                      Adapted from Richards, 2001
The VHL gene promoter lies approximately 60 bp upstream from the first 
methionine codon and is a GC-rich, TATA-less and CCAAT-less promoter with 
transcription initiating around a putative Sp-1 binding site (Kuzmin et al., 1995). It contains 
numerous predicted binding sites for transcription factors but it has not yet been revealed 
how VHL expression is controlled (Zatyka et al., 2002). The 3’ untranslated region in human 
contains 11 so-called Alu repeats and is in part conserved in rodents, however at present, 
no evidence exists that suggests a VHL-related functional role for these repeats. 
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1.3.2 The VHL protein (pVHL) 
 
The two VHL gene products pVHL30 and pVHL19 are both detectable in vivo and differ 
only by the additional presence of the afore-mentioned eight N-terminal acidic repeats 
characterising solely the longer pVHL form, pVHL30. As the functional distinction between 
the two VHL forms remains elusive to date and as both forms behave similarly in most 
functional assays, they are very often referred to generically as pVHL. Moreover, almost 
all inactivating mutations known so far lie within regions of the VHL gene that are 
common to both proteins leading to the assumption that both forms of pVHL have to be 
inactivated in order for tumours to arise. However a mutation found in the N-terminal 
acidic domain, P25L, has been identified in patients with sporadic pheochromocytoma and 
would suggest that there are different functions related to the two proteins (Van der Harst, et 
al., 1998). Furthermore the two pVHL forms differ in their subcellular localization: while 
pVHL19 is predominantly nuclear, pVHL30 localises to both nuclear and cytoplasmic 
compartments. In addition it has been shown that when pVHL30 resides in the cytoplasm it 
associates and stabilizes the microtubule network (Hergovich et al., 2003). pVHL has been 
shown to be subjected to nucleocytoplasmic shuttling mediated by Ran and to be also 
associated with the endoplasmatic reticulum (ER) (Schoenfeld et al., 2001; Groulx et al., 2000; Lee 
et al., 1996).  
pVHL, comprising both VHL gene products, is a tumour suppressor protein based 
on both genetic and functional criteria as tumour formation by VHL-defective renal 
carcinoma cells 786-O in nude mouse xenograft assays is suppressed after reintroduction of 
wild-type VHL (Gnarra et al., 1996; Iliopoulos et al., 1995).  
pVHL has two major, functionally distinct, structural domains:  the α- and the β-
domain (FIG.5b). While the smaller α-domain consists of 3 α-helices (aa 155-192), the β-
domain consists of a seven-stranded β sandwich (aa 63-154) and one α-helix (aa 193-204) 
(Stebbins et al., 1999). The α-domain is required for binding elongin C (aa 157-171) and the β-
domain provides the substrate-docking interface for target proteins, including the HIF-α 
subunits (see chapter 1.3.5). 
 
1.3.3 Genotype-Phenotype correlations 
 
When germline mutations (mutations present in all cells of an individual including the 
germ cells and that are therefore heritable) occur in the VHL gene, they confer the genetic 
risk of tumour formation in concert with somatic second VHL allele loss or DNA 
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methylation inactivation. Germline VHL mutations have been identified in more than 500 
VHL families worldwide and show considerable heterogeneity in both their type and their 
location within the VHL gene. Two-thirds of VHL patients harbour missense, nonsense, 
splice site mutations, and micro-deletions and –insertions, while in one-third large 
deletions of 4-380 kb can be found.  
As mentioned before, VHL disease has been classified into subcategories 
depending on the likelihood of pheochromocytomas to arise in a VHL patient and specific 
genotype-phenotype correlations are beginning to emerge in affected families (Table 1). 
Type1 disease is normally associated with mutations that lead to complete loss of the VHL 
gene product (deletion, frame-shift, nonsense and splice mutations) and the few missense 
mutations leading to type 1 have been mapped to residues in the hydrophobic core of the β-
domain causing probably complete unravelling of the pVHL structure. In contrast, the 
majority of missense mutations are associated with type 2 disease and mostly map to the 
binding site for elongin C, to the surface patch in the β-domain involved in binding HIF-α 
or are predicted to cause relatively localised effects if a structural residue is involved.  Type 
2C mutations (i.e. associated with pheochromocytoma only) promote HIF-α ubiquitylation 
in vitro, but are apparently incapable of binding and regulating the assembly of fibronectin 
(Clifford et al., 2001; Hoffman et al., 2001). This suggests that loss of other VHL functions than 
HIF-α regulation are necessary for pheochromocytoma susceptibility and raises the 
possibility that abnormal fibronectin matrix assembly contributes to pheochromocytoma 
pathogenesis in the setting of VHL disease.  Mutations causing type 1, type 2A and type 2B 
demonstrated variable effects on Hif-α and elongin binding, though resulting all in 
defective HIF-α regulation and loss of fibronectin binding. In summary HIF deregulation 
seems to have a causal role in HB and RCC, while there must be another cause for 
pheochromocytoma pathogenesis. A listing of all found germline and somatic VHL 
mutations assembled can be viewed under http:// www.umd.be (Beroud et al., 1998). 
 
1.3.4 VHL gene and protein expression 
 
VHL mRNA and protein are ubiquitously expressed implying that tissue-specific 
expression cannot account for the complex tumour pattern observed in VHL disease. For 
example, during human embryogenesis, VHL mRNA is expressed from as early as six 
weeks of gestation in virtually all tissues with particular high levels in urogenital system, 
brain, spinal cord, sensory ganglia, eyes and bronchial epithelium (Richards et al., 1996). In 
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addition it has been shown that VHL expression in the kidney is present in the proximal 
tubule, where RCC is postulated to arise, but also in the loops of Henle, which are normally 
never affected during the course of VHL disease (Richards et al., 1996; Kessler et al., 1995). The 
only study focusing on VHL mRNA expression during mouse embryogenesis documented 
similar widespread expression as in human (Kessler et al., 1995). 
Studies investigating the expression of the VHL protein also confirmed widespread 
VHL expression and demonstrated that pVHL is expressed especially in epithelial cells as 
those covering the body surface, the alimentary canal, and the respiratory and genitourinary 
tracts. In addition expression was found in cardiomyocytes, parenchymal cells of visceral 
organs, secretory cells of the exocrine and endocrine organs, neurons in nervous tissue, 
lymphocytes in lymphoid tissue and macrophages (Sakashita et al., 1999; Corless et al., 1997; Los 
et al., 1995). 
During the course of the thesis presented herein I was able to show cell-specific 
expression of VHL in two tissues, namely the retina and the cerebellum by using a newly 
created antibody recognizing specifically the mouse VHL protein. These new findings will 
be discussed in chapter 8. 
 
1.3.5 VHL function as part of an E3 ligase complex 
 
pVHL functions as the substrate recognition component of a complex termed VCB-Cul2, a 
stable multi-protein complex with elongins C and B, Cullin2 (Cul2) and Rbx1 (a RING box 
protein also called Roc1 and Hrt1) (FIG. 6).  (Kamura et al., 1999, Lisztwan et al., 1999; Pause et al., 
1997; Kibel et al., 1995; Duan et al., 1995). Cul2 is 
the scaffold for the E2 enzyme, Rbx1 and 
elongin C components of the complex. Rbx1 
functions to assist in recruiting the E2, while 
Elongin C bridges Cul2 and the substrate 
recognition component pVHL, while Elongin 
B stabilizes the complex. This multi-protein 
complex, whose correct assembly is directly 
mediated by association of amino acids 100-
155 of pVHL with the chaperonin protein 
TriC (also called CCT for cytosolic 
chaperonin-containing TCP-1) (Hansen et al., 2002; Feldman et al., 1999), has E3 ubiquitin-ligase 
activity and functions in conjunction with an E2 ubiquitin-conjugating enzyme to poly-
Figure 6. The VCB-Cul2 complex. The von
Hippel-Lindau tumour-suppressor protein (pVHL)
forms a protein complex (VCB-Cul2) with elongin C
(El C), elongin B (El B), Cul-2 (neddylated or not),
and Rbx1, which functions as an ubiquitin-protein
ligase (E3). The beta domain of pVHL binds directly
to the ODD domain of HIF-α subunits and directs
their ubiquitination in the presence of oxygen. 
   Adapted from Ivan & Kaelin, 2001
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ubiquitinate proteins which targets them for subsequent degradation via the 26S 





Figure 7. Many proteins that undergo regulated destruction are first covalently modified by the attachment of a polyubiquitin
tail, which serves as a signal for degradation by a multiprotein complex of proteolytic enzymes called the proteasome.
Substrate-specific poly-ubiquitylation involves the sequential action of the E1 ubiquitin activating enzyme, an E2 ubiquitin-
conjugating enzyme and an E3 ubiquitin ligase. Ubiquitination is a multistep process that conjugates ubiquitin moieties to
internal lysine residues of proteins and successive conjugation of ubiquitin molecules generates polyubiquitin chains.
Polyubiquitinated proteins are then degraded by the 26 S proteasome 
 To date, the most intensely studied and best-understood substrates of the VCB-
Cul2 complex are the α-subunits of the heterodimeric Hypoxia inducible factor (HIF) (see 
1.3.5.1) (Iwai et al., 1999). In the presence of oxygen, hydroxylated HIF-α interacts with the 
β-domain of VHL in the VCB-Cul2 complex, which targets HIF-α for degradation by the 
ubiquitin-proteasome pathway (Min et al., 2002; Tanimoto et al., 2000). Under hypoxic 
conditions or in the absence of functional pVHL, HIF-1α and HIF-2α are stabilized and 
accumulate resulting in elevated transcription of a wide variety of HIF-controlled genes 
such as VEGF, erythropoietin, glucose transporter GLUT1, TGF-β and TGF-α (Maxwell et 
al., 1999; Iliopoulos et al., 1996). Overproduction of these angiogenic factors contributes to the 
highly vascularized tumours that develop in VHL patients.  
 
1.3.5.1 Hypoxia inducible factor (HIF) 
 
The hypoxia-inducible factor HIF-1α is a key regulator of responses to hypoxia through 
transcriptional activation of a variety of genes linked to processes such as angiogenesis, 
glucose uptake and metabolism. HIF is a heterodimeric transcription factor consisting of an 
α-subunit (usually HIF-1α, other family members are HIF-2α and HIF-3 α, which will be 
discussed at the end of this subchapter) and HIF-1β (also called ARNT for aryl 
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hydrocarbon receptor nuclear translocator), which are basic helix-loop-helix (bHLH) 
proteins of the PAS family (named after Per, ARNT and Sim, which were the first 
members to be recognized). While the nuclear β-subunit is constitutively expressed, the α-
subunit is the regulatory component, which is labile under normoxia and targeted by the 
VCB-Cul2 complex for ubiquitination and subsequent degradation. Under hypoxic 
conditions though, HIF-α accumulates, becomes phosphorylated, dimerizes with HIF-β and 
binds to specific DNA sequences, hypoxia-response elements (HRE), in the cis-regulatory 
regions of hypoxia-inducible genes activating their transcription (general reviews Lee et al., 
2004; Maynard & Ohh, 2004). 
The interaction of pVHL with HIF-1α requires the latter to be enzymatically hydroxylated 
at two conserved proline (P) residues, P402 and P564, each within a Leu-X-X-Leu-Ala-Pro 
sequence motif (Masson et al., 2001). This oxygen dependent hydroxylation is carried out by 
proline hydroxylases and is required for HIF-α to participate in two essential hydrogen 
bonds with hydrophilic side chains that are located in the VHL β-domain (Hon et al., 2002; 
Bruick & McKnight, 2001; Ivan et al., 2001; Epstein et al., 2001; Jaakola et al., 2001;Ohh et al., 2000). In 
human there are three prolyl hydroxlase isoforms, PHD 1-3, among which PHD2 has been 
proposed to be the primarily responsible for HIF hydroxylation under normoxia (Berra et al., 
2003). The VHL-binding site of HIF-1α lies within a region termed the oxygen-dependent 
degradation (ODD) domain, which overlaps with the amino-terminal transactivation 
domain (N-TAD) of HIF-1α, and which confers protein instability in the presence of 
oxygen. The second transactivation domain of HIF1-α lies in the carboxy-terminus (C-
TAD) and activates transcription solely under hypoxia as under normoxia a specific 
asparagine residue, N893, is hydroxylated by a HIF asparaginyl hydroxylase called FIH 
(factor inhibiting HIF) (Lando et al., 2002; Mahon et al., 2001). Hydroxylation at this site 
prevents recruitment of the co-activator proteins p300 and CBP (cyclic-AMP-response-
element-binding-protein (CREB)-binding protein). HIF is therefore regulated at the level of 
protein turnover by prolyl hydroxylation, which serves as a signal for pVHL binding, and 
at the level of co-activator recruitment by asparaginyl hydroxylation (FIG. 8).  
In addition, normoxia also stimulates binding of a protein acetyl-transferase named 
ARD1 to HIF-1α that acetylates lysine 532 in the ODD domain. This acetylation has been 
shown to increase the interaction of HIF with VHL promoting its proteasomal degradation, 
but the mechanism is still unknown (Jeong et al., 2002). The VHL-HIF-α complex has been 
shown to have in addition another binding partner, the Tat-binding protein TBP-1 (which is 
                      16
                                                                                                                                    Von Hippel-Lindau disease 
an ATPase subunit within the 19S regulatory particle of the 26S proteasome) that seems to 
regulate the proteasomal degradation of HIF-α (Corn et al., 2003). 
Figure 8. Hydroxylation of HIF-α and the
regulation of hypoxia-inducible genes. In the absence
of oxygen (left side), HIF- α is bound by the
transcriptional coactivators p300/CBP and dimerizes
with HIF-β. It then binds to hypoxia-responsive
elements (HREs), initiating the transcription of
numerous hypoxia-inducible genes. In the presence of
oxygen, HIF- α is hydroxylated on conserved pralines
bz prolyl hydroxylases (PHDs) and on asparagine at
position 803 by the factor inhibiting HIF (FIH)
enzyme. Prolyl hydroxylation promotes HIF- α
recognition by the b-domain of pVHL and subsequent
ubiquitination by the VCB-Cul2 complex, resulting in
HIF- α degradation via the 26S proteasome. In
addition, the asparaginyl hydroxylation prevents
p300/CBP from binding HIF- α, thus also inhibiting
transcription of hypoxia-inducible genes. B and C,
elongin B and elongin C respectively; Cul2, cullin 2;
Ub, ubiquitin. 
          Adapted from Sufan et al., 2004 
 
In human there are in total three HIF-α genes: besides HIF-1α there are the 
homologues HIF-2α (also called EPAS1 and MOP2) and HIF-3α, which have structural 
similarities but seem to have different functions (Park et al., 2003). While HIF-1α is 
ubiquitously expressed, HIF-2α expression is e.g. high in the mouse lung, where it has been 
implicated in the development of the tubular system, and in vascular endothelial cells 
where it is involved in vascular remodelling (Wiesener et al., 2003; Brusselmans et al., 2001; Jain et 
al., 1998; Tian et al., 1997). Interestingly, in the kidney both HIF-1α and HIF-2α are abundantly 
expressed, but only HIF-2α overexpression promotes growth of renal carcinoma cells and 
its inhibition is sufficient to suppress this growth (Kondo et al., 2002 and 2003). Therefore, 
although HIF-1α and HIF-2α are very similar, also binding as dimers with HIF-1β the same 
DNA sequences, they might have a different tissue or cellular expression resulting possibly 
in activation of different target genes. The fact that both HIF-1α- and HIF-2α-knockout 
mice have been shown to be embryonically lethal suggests that the two genes actually have 
distinct functions (Iyer et al., 1998; Ryan et al., 1998; Tian et al., 1998; Peng et al., 2000). HIF-3α is 
the least characterized of the three HIF-α subunits and is unique as the gene gives rise to a 
multitude of splice variants and lacks the N-TAD (Maynard et al., 2003). One of these 
alternative splice variants of HIF-3α, the inhibitory PAS domain protein (IPAS), has been 
shown to act as a dominant negative regulator of HIF-1α and HIF-3α might therefore 
generally act as an antagonist of the HIF system (Makino et al., 2002).  
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The dysregulation of the HIF transcriptional cascade has extensive effects that 
make it difficult to distinguish whether, and to what extent, observed matrix-related 
abnormalities in VHL-defective renal carcinoma cells [including abnormal fibronectin 
assembly, defective formation of fibrillar adhesions and changes in branching 
morphogenesis and migration (Esteban-Barragan et al., 2002; Kamada et al., 2001; Davidowitz et al., 
2001; Koochekpour et al., 1999; Ohh et al., 1998)] represent effects on pathways that are related or 
distinct from HIF. In C. elegans it has now been shown recently, by studying and 
comparing effects of VHL inactivation on gene expression patterns in wild-type versus 
HIF1-defective backgrounds, that there are HIF-dependent and –independent effects, 
linking a HIF-independent VHL pathway with extracellular matrix function (Bishop et al., 
2004). 
 
1.3.5.2 Other targets of the VCB-Cul2 E3 ligase complex   
 
Additional potential targets of the VBC-Cul2 E3 ligase complex may be: 
• the atypical protein kinase C (aPKC) isoforms λ αnd ζ that have been shown to 
bind to VHL though its β-domain. At least for PKCλ it has been shown that VHL 
as part of the E3 ligase complex mediates its ubiquitination (Okuda et al., 1999) 
• the VHL-interacting de-ubiquitinating (VDU) enzymes 1 and 2 ( Li et al., 2002) 
• the seventh subunit and the large subunit of RNA polymerase II  (Kuznetsova et al., 
2003; Na et al., 2003) 
 
1.3.6 Other functions of VHL 
 
VHL role in transcripton (beyond HIF) 
Apart form the hypoxia-responsive pathway pVHL is capable of regulating the 
transcription of certain other genes independently of HIF. Among these are the 
transcription factor SP1 (Rafty et al., 2002; Cohen et al., 1999) and the pVHL-associated KRAB-
A domain-containing protein (VHLaK) transcription repressor (Li et al., 2003). 
 
VHL role in CNS development 
Investigation of the putative role of VHL in the CNS development by using rodent 
progenitor cells showed that neuronal differentiation is induced by VHL gene transduction 
and correlates with pVHL-expression (Murata et al., 2002; Kanno et al., 2000). In this specific 
experiment a VHL mRNA antisense oligonucleotide approach inhibited the CNS 
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progenitor cell differentiation and upregulated their cell cycle fitting to a putative role for 
VHL in cell-cycle control as also discussed in the next paragraph. 
 
Link between pVHL and cell-cycle control 
A potential involvement of VHL in cell cycle control was suggested as it has been shown 
that cells lacking pVHL, such as the renal cell carcinoma cell line 786-O, overexpress 
cyclin D1 and downregulate the cyclin-dependent kinase (cdk) inhibitor p27 and exhibit an 
impaired ability to exit the cell cycle following serum withdrawal (Bindra et al., 2002; Pause et 
al., 1998). Moreover, forced overexpression of pVHL leads to upregulation of p27 (Kim et al., 
1998). But up to this point no evidence was given that there is a direct link between VHL 
and p27. Moreover different results are emerging making it difficult to understand this 
potential link (Goda et al., 2003, Wang et al., 2003). 
 
Link between VHL and the extracellular fibronectin matrix 
Renal cell carcinoma cells lacking VHL are deficient in proper fibronectin matrix assembly 
and VHL has been shown to associate directly with fibronectin in order to promote proper 
matrix assembly (Esteban-Barragan et al., 2002; Ohh et al., 1998). This association is somehow 
dependent on the neddylation of VHL as a neddylation-defective pVHL mutant fails to 
promote proper fibronectin matrix assembly (Stickle et al., 2004).  
Type 2C mutant, predisposing solely to pheochromocytoma, have been linked to 
fibronectin assembly, as their binding capacity to fibronectin is impaired while the E3 
ubiquitin ligase complex is functional. This would actually suggest that these would be 
gain-of function mutations as type1 VHL disease patients have no or a low risk for 
pheochromocytomas (Hoffman et al., 2001). 
 
Link between VHL and tumour growth and metastasis 
pVHL has an effect on matrix metalloproteinases (MMPs) and their tissue inhibitors of 
matrix metalloproteinases (TIMPs), which is independent of the hypoxia-responsive 
pathway. Loss of VHL function regulated negatively TIMPs, such as TIMP2, while 
upregulating MMPs (2 and 9) (Koochekpour et al., 1999). As MMPs are important in 
angiogenesis, morphogenesis and tissue remodelling and have been associated with cellular 
invasiveness (Lafleur et al., 2003), the regulation by VHL attributes a role to VHL in tumour 
growth and metastasis. In addition lack of functional VHL has been associated with 
overproduction of carbonic anhydrases 9 and 12 (CA9 and CA12), which favour the 
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growth and invasive properties of tumour cells by their involvement in the acidification of 
the tissue microenvironment (Ivanov et al., 1998). 
  
Link between VHL and microtubules 
VHL has been recently shown to bind to and stabilize microtubules (Hergovich et al., 2003) 
and even more recently it has been proposed that VHL changes the behaviour of MTs 
dependent on their subcellular localization (Lolkema et al., 2004). This implies a role for VHL 
in cellular processes such as migration, polarization, and cell-cell interactions.  
 
1.4 mVHL-the mouse homologue of VHL 
 
The VHL gene sequence has homologues in the nematode worm C. elegans (Woodward et al., 
2000) and in Drosophila (Adryan et al., 2000; Aso et al., 2000) and it is highly conserved in 
primates and rodents. Sequence conservation is particularly high across regions known to 
be involved in binding to other proteins or in maintaining the pVHL structure, and 
conservation of function has been confirmed in Drosophila. 
The murine VHL gene also gives rise to two proteins, pVHL25 and pVHL21, which, 
in contrast to the human homologue, have only one acidic repeat within the N-terminal 
19aa that distinguishes them (Gao et al., 1995). 
 Several groups have attempted to develop a mouse model that mimics the 
phenotypic features of VHL disease. The complete VHL knockout published in 1997 
revealed an essential role for pVHL in development as homozygous animals died between 
day E10.5-E12.5 due to vascular abnormalities in the placenta. Heterozygous mice on a 
C57BL/6 background though were phenotypically normal (Kleymenova et al., 2004; Gnarra et 
al., 1997). Heterozygous VHL mice on a BALB/c background were later shown to develop 
blood vessel tumours in the liver (hepatic hemangiomas) (Haase et al., 2001) and this implies 
that the strain background must have an impact on the observed phenotypes. To avoid 
embryonic lethality Haase et al. utilized Cre/loxP site-specific recombination using an 
albumin promoter driven Cre recombinase to conditionally inactivate the VHL gene in the 
liver. They could confirm that homozygous deletion of VHL in the liver resulted in hepatic 
tumours leading to death at 6-12 weeks (Haase et al., 2001).  However no other organ was 
affected in this conditional VHL knockout model.  
In another attempt to produce a VHL conditional knockout mouse model that more 
closely mimicked human VHL disease a human β−actin promoter-driven cre transgenic 
mouse that expresses cre in a mosaic pattern in multiple organs was utilized (Ma et al., 2003). 
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In this case loss of pVHL resulted in an extensive abnormal vascular phenotype in multiple 
mouse organs, which appears consistent with the ability of pVHL to control the expression 
of genes whose product participate in angiogenesis, a crucial stage in tumour progression.  
Recently it has been shown that VHL has a crucial role in endochondral bone 
development by conditional inactivation of murine VHL in all cartilaginous elements 
(Pfander et al., 2004). The mice were viable, but grew slower than control littermates 
developing a severe dwarfism. VHL is therefore necessary for normal chondrocyte 
proliferation in vivo. This is in contrast to the idea that VHL actually helps cell cycle exit. 
However these findings are consistent with another report that lack of pVHL inhibits cell 
proliferation in a teratocarcinoma model (Mack et al., 2003). It is therefore possible that 
pVHL actions on the cell cycle vary in different cell types. 
In the thesis presented herein we first tried to create a conditional VHL mouse 
where exon 1 of VHL would have been flanked by loxP sites (see also chapter 3), a so-
called floxed VHL mouse. Unfortunately in our case it didn’t work out, but it was 
published at the same time by Haase et al.. The availability of these floxed VHL mice 
allowed us to create a conditional VHL knockout model in the brain with severe impacts on 
the brain development as shown in chapter 9. 
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Chapter 2 
 
The Retina and Cerebellum 
-A closer look at two tissues in the context of VHL disease- 
 
VHL disease is characterized by a defined subset of tumours that can be found only in 
specific tissues (as presented in chapter 1). Given the fact that VHL is expressed in a 
multiplicity of tissues, a broad distribution of tumours arising from mutations in the VHL 
signalling axis would be expected. Nevertheless this is not the case with the retina and 
cerebellum being primarily affected in VHL patients. It is thus likely that the tissue context 
is a major factor dictating tumour formation driven by VHL inactivation. 
To investigate in more detail the VHL protein expression pattern in specific tissues 
we decided to focus on the retina and the cerebellum, as both tissues can be affected by the 
same type of blood-vessel tumour, a so-called hemangioblastoma, and as this type of 
tumour is among the most common and widespread features of the VHL disease. We hoped 
to gain more insight into possibly tissue-specific expression and roles of VHL that would 
allow hypotheses about the origin of hemangioblastomas to be put forward, as this is still a 
matter of debate. The results of this expression study are presented in chapter 8, whereas 
this chapter is meant to give a short overview of the retina and the cerebellum and their 
respective development, especially in the mouse.  
 
2.1 The Retina 
 
The retina is a thin sheet of neural tissue lining the back of the eye, which is involved in 
light detection (FIG. 9). It consists of seven major cell types, six types of neurons and one 
glial cell type, organized into three main cellular layers: the outer nuclear layer (ONL) 
comprising the nuclei of the rod and cone photoreceptor cells, the inner nuclear layer (INL) 
comprising the nuclei of interneurons (such as bipolar, horizontal and amacrine cells) and 
Müller glial cells, and the ganglion cell layer harboring the ganglion cells (GCL). The 
situation in the retina is even more complex than depicted here as all of the seven major 
cell types have in turn subtypes. So in the end mammalian retinas contain approximately 55 
distinct cell types all serving unique roles in the intricate circuitry of the retina (Masland, 
2001). 
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Figure 9. Overview of the morphology of the eye and focus on the retina. On the left a schematic sagittal section through an 
eye is depicted. From the top: the RPE is a non-neuronal cell layer whose apical processes surround the outer segments of the 
photoreceptor cells, namely rods and cones. Rods and cones stretch over three layers named the outer segment, the inner segment and the 
ONL. The outer segment herein contains stacks of membranous discs rich in the visual pigment rhodopsin, the inner segment contains 
the machinery of the cells (like the mitochondria, golgi apparatus and endoplasmic reticulum) and the ONL the nuclei. The OPL layer 
contains many axons of horizontal cells and the dendritic trees of bipolar cells, whose nuclei are found together with nuclei of the 
amacrine and Müller glial cells in the INL. Bipolar and amacrine cells extend their axons also into the IPL. In the GCL a second 
population of amacrine cells can be found together with the ganglion cells. And finally, the ONF consists of axons of the ganglion cell 
layer that make up the optic nerve and ultimately carry retinal signals into the brain.  
 
 The retina is able to receive a light signal that is focused on its surface and convert 
this signal to a neural message, which is then conducted to a cortical area of our brain 
responsible for sight. Light passing through the cornea is focused by the lens on the outer 
segments of the rod and cone photoreceptors in the ONL. After the absorption of various 
wavelengths of light by the photoreceptors, the information gets transmitted to the bipolar 
neurons found in the INL that integrate this information and transmit the signal to the 
ganglion cells, which in turn send the information through the optic nerve to the brain for 
higher order processing. The horizontal cells and the amacrine cells, which provide lateral 
connections in the INL, can modulate these direct signaling circuits.  
The cone photoreceptor cells function in bright light amplitudes and are responsible 
for colour vision, whereas the rods are sensors of dim light and do not discern colour. 
Human vision relies heavily upon cones, of which there are three types-blue, green and red- 
and uses only one variety of rod photoreceptor. By contrast mice and rats rely almost 
entirely on rod-mediated vision. Approximately 76 % of all cells in the mouse retina are 
photoreceptors and about 97 % of these are rods. In addition mice also don’t have the 
centrally localized cone-rich region named the fovea normally found in humans in the 
center of a yellowish spot called macula (Morrow et al., 1998). Among the various cell types 
that can be found in the inner nuclear layer bipolar cells make up ca. 41 % of all cells in the 
layer, amacrine 39 %, Müller cells 16 % and horizontal cells 3 % (Jeon et al., 1998). 
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The one non-neuronal cell type found in the retina, the Müller glial cell, plays very 
important roles in supporting neuronal survival and information processing and will be 
elucidated further in chapter 2.1.1. 
 
2.1.1 Müller glial cell 
 
The vertebrate retina contains a specialized and very unique type of glial cell, the Müller 
glia, which spans the entire thickness of the retina contacting every type of neuronal cell 
body and process (FIG. 10). As a reflection of this morphological relationship, the Müller 
glial cells play a crucial role in supporting neuronal survival and information processing 
(for reviews Newman & Reichenbach, 1996; Bringmann & Reichenbach, 2001).  
Müller glial cells:  
1)   are responsible for the structural stabilization of the retina 
2) regulate the extracellular homeostasis of relevant ions, 
including pH, and of the water content of the extracellular 
space  
3) deliver trophic substances to neurons and remove metabolic 
end-products 
4) metabolize glucose to lactose, which is preferentially taken up 
by photoreceptors as a source of energy for their oxidative 
metabolism 
5) play a crucial role in the glutamate-glutamine cycle within the 
retina as glutamate is degraded in Müller glial cells leading to 
(among others) synthesis of glutamine by the glutamine 
synthetase and to synthesis of glutathione Figure 10. Drawing of aMüller glial cell
depicting its positioning
in the context of the
retinal tissue. 
             Dyer & Cepko, 2000
6) act as intra-retinal modulators of immune and inflammatory 
responses 
7) release VEGF in reponse to hypoxia and induce neovascularization of the retina          
(Eichler et al., 2000)  
 
Interestingly, virtually every alteration, injury or disease of the retina is associated 
with morphological, cellular and molecular changes of Müller glial cells, a process called 
reactive gliosis. This process is characterized by proliferation, changes in cell shape due to 
alteration in intermediate filament production, changes in ion transport properties and 
secretion of signaling molecules such as vascular endothelial growth factor (VEGF). In 
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response to experimental retinal injury, Müller cells have been shown to down-regulate 
their expression of the tumour suppressor protein p27Kip1 (which is expressed exclusively in 
this retinal cell type after differentiation, see also chapter 2.1.2), resulting in Müller cell 
proliferation and suggesting that post-mitotic Müller glia have an intrinsic requirement for 
p27 in maintaining their differentiated state (Dyer and Cepko, 2000). The proliferation initiated 
by p27 downregulation is transient and reaches a maximum 24 hours after injury. Then 
proliferation ceases due to downregulation of cyclin D3, which is accompanied by 
upregulation of GFAP (glial fibrillary acidic protein). Gliosis is extremely important for the 
protection and repair of retinal neurons and Müller cells are also potential sources for 
neural regeneration within the postnatal retina (Fischer & Reh, 2003 and 2001) as they retain 
their capability to dedifferentiate and proliferate. 
In contrast to the wealth of information available regarding Müller cell function, 
there are several areas where current knowledge of Müller cell biology is rudimentary as 
e.g. very little is known about the mechanisms concerned with Müller cell development 
and determination, or the actual role of Müller cells in retinal development. In addition 
there is also a scarcity of knowledge as to whether there is a direct involvement for Müller 
glial cells in retinal disorders. 
 
2.1.2 Development of the retina 
 
The retina develops as an outgrowth of the neural tube known as the optic vesicle and is 
accomplished by postnatal day P8 in the mouse. By E9.5 the fates of the inner and outer 
layers of the optic cup are clearly different. While the outer layer remains as a monolayer 
of cuboidal cells that will give rise to the pigment layer of the epithelium, those cells in all 
but the periphery rapidly multiply giving rise to multilayers of cells which differentiate to 
form the various components of the neural retina. Retinal progenitors are initially arranged 
as a pseudo-stratified neuroepithelium, whereby cells contact both surfaces of the optic 
cup. During mitosis cells forego these contacts and divide at the outer surface. 
 In the murine retina the diverse retinal cell types derive from a pool of proliferating 
pluripotent precursor cells and are generated by spatial and temporal differentiation during 
development in a characteristic order (Ahmad et al., 1999; Turner & Cepko, 1987). Birth-dating 
studies have shown that retinal cell types are generated in overlapping but well-defined 
intervals with ganglion cells, cone photoreceptors, amacrine cells, and horizontal cells 
generated prior to birth and bipolar neurons and müller glia generated after birth (FIG. 11) 
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(Young et al., 1985). The formation of rod 
photoreceptors occurs pre-and postnatally 
with a peak of genesis coincident with the 
day of birth in the mouse.  
The “competence model” of retinal 
cell fate specification states that the 
instrinsic ability (the competency) of 
mitotic retinal progenitor cells to produce 
a particular cell fate in response to the 
retinal environment changes continuously throughout development (Livesey et al., 2001; Cepko 
et al., 1996). Once a cell passes through a particular developmental stage, it is only 
competent to become “later born” cells. In addition to the contribution of intrinsic 
determinants of cell fate specification extrinsic factors play also a major role.   
Figure 11 . The course of retinal histogenesis. 
  
Terminal cellular differentiation is thought to be associated with irreversible cell 
cycle exit. The proportion of cells that exit the cell cycle at each developmental stage must 
be regulated carefully, because if too many cells exit the cell cycle during early stages of 
development there might be an increase in the proportion of early-born cell types at the 
expenses of later-born cell types. The decision to divide or to exit the cell cycle occurs 
during the first gap phase of the cell cycle, G1, which is governed by cyclin-dependent 
kinases (CDKs), whose activity can be negatively regulated by so called cyclin-dependent 
kinase inhibitors (CDKI) (Sherr and Roberts, 1999). The cyclin-dependent kinase inhibitor 
protein, p27Kip1 , among other members of the Cip/Kip familiy of CDKIs such as p57Kip2, 
has been shown to be expressed in the retina in a temporal pattern coincident with the onset 
of differentiation of most retinal cell types (Cunningham et al., 2002; Dyer and Cepko, 2001; Levine 
et al., 2000). In addition overexpression of p27Kip1 has been shown to inhibit proliferation of 
progenitor cells.  
Accompanying and following retinal cell differentiation, apoptosis can be observed 
in the retina (Voyvodic et al., 1995). In this context, apoptosis presumably plays an important 
role in establishing the proper ratios of the cell types and in fine-tuning the retinal 
connections. 
Little was known of the cell and molecular biology of progenitor cells, or of the 
transcriptional networks that define their intrinsic states that change during development. 
But detailed analysis of genes expressed in these cells and the identification of expression 
profiles characteristic for this cell type are currently emerging (Blackshaw et al., 2004 and 2001; 
                      26
                                                                                                                                                      The Cerebellum       
Livesey et al., 2004). As mentioned already above, the p27 and p57 CDKIs are e.g. expressed 
at different times during the cell cycle in the mouse retina suggesting that this reflects their 
different roles in regulating retinal progenitor cell cycle exit. In addition retinal cells use 
different components of the cell cycle machinery over the course of development, e.g. 
cyclin D1 during embryonic and perinatal stages, whereas cyclin D3 is expressed in a 
restricted population of progenitors towards the end of retinal histogenesis. A number of 
homeodomain transcription factors such as Chx10 and Six3 have also been identified 
shown to regulate the proliferation of retinal progenitor cells and the specification of cell 
fate (Dyer, 2003). Crx, an otx-like homeobox gene, has been shown to be expressed in 
photoreceptor and regulates photoreceptor differentiation (Furukawa et al., 1997). And 
regarding gliogenesis, recent studies demonstrated that activation of the Notch signaling 
pathway can play a role in regulating Müller cell development (Furukawa et al., 2000; Vetter & 
Moore, 2001). Furthermore p27, apart from regulating proliferation of Müller glia in response 
to stress or injury, can probably also promote their development, although there are some 
contrasting results from xenopus and mice (Vetter & Moore, 2001).  
In summary, despite all these recent findings, there are still many open questions 
regarding the mechanism underlying the coordination of proliferation and cell fate 
specification to be addressed in order to attain a better understanding of retinal 
development.  
 
2.2 The Cerebellum 
 
The cerebellum is the primary center for fine motor control of movement and posture found 
in the central nervous system (CNS). It is a relatively simple 
CNS structure with well-defined anatomy and physiology and 
can be morphologically divided into a central vermis, which is 
flanked by lateral hemispheres (FIG. 12). Both the vermis and 
hemispheres are further subdivided by a series of parallel fissures 
defining a conserved pattern of folia.  
 The mammalian cerebellum consists of deep centrally 
located neurons, referred to as the deep nuclei, and a peripheral 
cortex. This cortex contains two principal neuronal subtypes, the Purkinje cells, which are 
inhibitory, γ-aminobutyric acid (GABA) releasing neurons, and the cells of the internal 
granular layer (IGL), the glutamate-releasing, excitatory granule neurons. Each neuronal 
Figure 12. Dorsal view of an
adult mouse cerebellum. The
cerebellar vermis (CV) and the
hemispheres (CH) are
indicated. 
           Chizkov et al., 2003
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cell type has a stereotypic and distinct morphology and is located in a discrete lamina 
within the cerebellum (FIG. 13). 
 
Figure 13. Sagittal section through a mouse 
cerebellum. The outer portion of the cerebellum is 
composed of grey matter in two layers: the molecular 
layer (ML; outer, lighter) and the granular layer (GL; 
inner, dark; also called internal granular layer to 
distinguish from the external granular layer present during 
development). The white matter is seen in the middle of 
the cerebellum (WM). Purkinje cells (PL) are large 
neuronal cells with numerous dendrites, which mainly 
form the border between the molecular layer and the 
internal granule cell layer. The star in the left picture 
arks cells of the deep cerebellar nuclei 
   
 
The connections between the principal neu
circuitry that is repeated throughout the cerebellum
movement and the position of the body is se
‘precerebellar system’, a group of nuclei in the 
brainstem. These nuclei in turn project to granule 
cells, which communicate with the Purkinje cells. In 
parallel the inferior olivary nucleus from the brain 
stem projects directly to Purkinje cells. The 
Purkinje neurons then provide the primary output 
from the cerebellar cortex by projecting to the deep 
cerebellar nuclei, which then finally project to the 
cerebral cortex, mediating the fine control of motor 
movements and balance. In addition to the already-
mentioned cerebellar neurons there are three additional classes: Golgi cells, which contain 
GABA and glycine and provide feedback inhibition to granule neurons, and the GABA-
releasing stellate and basket cells, which modulate Purkinje cell output.  
 The murine cerebellum contains ca. 108 granule cells, which control the activity of 
the Purkinje cells. These cells are critical for normal cerebellar function as mutant mice 
with a loss of granule cells suffer from severe ataxia (Hamre & Goldowitz, 1997). 
 
2.2.1 Development of the cerebellum 
uch of what is known about the cerebellum comes from information provided by 
investigations in mice, especially by using mutant mice. Given the high degree of 
m
rons are arranged in a stereotyped 
 (FIG. 14): sensory information about 
nt to the cerebellum via the so-called 
Figure 14. The circuitry of t
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conservation of cerebellar anatomy and function between human and mouse, an 
understanding of mouse cerebellar development has provided insights into human 
cerebellar development.  
The cerebellum develops from the dorsal region of the posterior neural tube and the 
neural populations of the cerebellum arise from at least two different germinal zones. 
While most of the cells, including the Purkinje cells, arise from the ventricular germinal 
matrix or zone (VZ), granule cell precursors come from a specialized germinal matrix 
called the rhombic lip. The proliferating cells of the rhombic lip, which are committed to 
become external granular layer (EGL) neurons, start by E13 to disperse rostrally over the 
surface of the cerebellar anlage, where they establish the EGL. The EGL contains dividing 
granule neuron progenitors and proliferation of precursors continues until P15, when the 
layer finally disappears. By E18.5 the EGL is normally about eight cells thick. Starting at 
birth and until day P20, when maturation of the cerebellum is complete, the post-mitotic 
granule cells leave the EGL to migrate inwards in order to form the internal granular layer 
(IGL). In the IGL the granule neurons then terminally differentiate. Migrating neurons are 
probably guided by Bergmann radial glia fibers through the molecular layer and, before 
reaching the IGL, they pass through the Purkinje neuron layer (PL) containing the cell 
bodies of Purkinje neurons and Bergmann glia. Purkinje cells appear at around E13, at 
which time they exit the cell cycle and migrate along the radial glial fibre system to the 








Figure 15. Schematic diagram of the developing cerebellum. During early developmental stages (left, E13 and E16), 
both of the principal neuron classes are specified. While Purkinje cells become postmitotic (filled circles) and migrate 
through the wall of the cerebellar anlage, precursors of the granule cell (unfilled circles) sweep across the roof in a 
morphogenetic movement. In the perinatal period (third panel from left, P6), granule cells become postmitotic and 
migrate inward, along the Bergmann glia, to assume a position deep below the Purkinje cell. In the adult (right), the 
pattern of connections of the granule neuron and the Purkinje cell (coronal plane) are established. Granule cells extend 
parallel fibers, which form synaptic connections with the dendrites of the Purkinje cells. EGL, External germinal layer; 
PL, Purkinje cell layer; VZ, ventricular zone; WM, white matter; IZ, intermediate zone: IGL, internal germinal layer. 
                                               Adapted from Hatten, 1999 
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The signals and the mechanism underlying control of granule cell proliferation and 
transition to terminal differentiation are starting to be uncovered and imply a variety of 
factors that are expressed at specific points either during proliferation, exit of cell-cycle, 
migration and terminal differentiation (reviews: Komuro & Yacubova, 2004; Sotelo 2004; Chizhikov 
& Millen, 2003; Kagami & Furuichi, 2001; Wang & Zoghbi, 2001; Hatten et al., 1999; Goldowitz & Hamre, 
1998). For example in the outer EGL, where only proliferating precursor cells can be found, 
there is a strong expression of a factor termed Math1, that has been shown to be required 
for the genesis of granule cells (Jensen et al., 2004; Ben-Arie et al., 1997). When granule neuron 
precursors then start exiting the cell cycle, becoming post-mitotic, they are in a state of pre-
migration and can be found more in the inner EGL. The change from proliferating to post-
mitotic state has been shown to be affected by the cyclin-dependent kinase inhibitor p27, 
which is expressed in the inner two third of the EGL, partly overlapping with the 
proliferating pool of granule cell precursors (Miyazawa et al., 2000). Mice lacking p27 have an 
increased level of proliferation and therefore a larger cerebellum and this further 
emphasizes the need of p27 expression for granule cell precursors to start differentiating. In 
addition it has also been shown that mature granule cells in the inner granular layer express 
p27 again, whereas this expression cannot be detected during the migration of the 
postmitotic precursor cells through the molecular layer into the IGL. 
But in addition to these intrinsic factors also extrinsic factors play a role. As an 
example, Sonic hedgehog (SHH) secreted by the Purkinje cells plays an important role in 
the development of granule cells (Lewis et al., 2004; Dahmane & Altaba, 1999). Furthermore, 
CXCR4, a recently identified target gene of HIF, has been shown to be present on granule 
cell precursors where it plays a role together with its ligand, stromal-derived factor (SDF1) 
(expressed from pial cells) to enhance the SHH induced proliferation of granule cell 
precursors (Staller et al., 2002; Klein et al., 2001).  
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Chapter 3 
 
Generation of mutant mouse strains by gene targeting 
 
Gene targeting techniques have revolutionarized the field of mouse genetics and allowed 
the analysis of diverse aspects of gene function in vivo in the context of the whole animal. 
Defined as the targeted alteration of a specific DNA sequence in its genomic locus, ‘gene 
targeting’ occurs as a result of a process called ‘homologous recombination’ in which two 
DNA entities, with a high sequence homology, interact and recombine, i.e. exchange 
genetic information by adding or replacing their sequence elements. Gene targeting by 
homologous recombination can lead to inactivation or alteration of gene expression 
(“knock-out” /loss of function or “knock-in” /gain of function mutation respectively). By 
this means it has therefore become possible to engineer mice with specific genetic 
alterations that have become an invaluable new tool to produce mouse models of human 
inherited diseases (for reviews Mueller, 1999).   
Nowadays, a routinely used 
technique to modify the mouse genome at 
any chosen locus employs homologous 
recombination in embryonic stem (ES) 
cells (Capecchi, 1989; Evans and Kaufmann, 
1981; Martin, 1981). ES cells are derived 
from pluripotent, uncommitted cells of the 
inner cell mass (ICM) of a pre-
implantation embryo, called a blastocyst, 
collected from a donor mouse 3.5-days 
p.c. (post coitum; after fertilization) (FIG. 
16). These cells behave like ordinary 
somatic cells when cultured in vitro and 
prevented from differentiating by culturing 
on an irradiated feeder layer of fibroblasts, 
which secret Leukemia Inhibitory factor 
(LIF). LIF is very often also supplemented 







Figure 16. Establishment of pluripotent Embryonic Stem
(ES) cells. A blastocyst is placed on a feeder cell layer,
which provides a matrix for attachment and prevents ES cell
differentiation. As the blastocyst is cultured, the outer layer
of differentiated cells (trophectoderm) attaches and spreads,
exposing the inner pluripotent cells (inner cell mass or
ICM). The ICM is then extracted, mechanically dissociated,
and the resulting cell clumps transferred onto fresh feeder
cells. After culture, colonies, which exhibit appropriate
morphology, are separated, dissociated into single cells, and
seeded onto a feeder layer. Those cells that form ES
colonies are further passaged to obtain permanent cell lines 
                    Drawing adapted from cba.musc.edu/COBRE/ CORE-B/Resources-B.html
         Text adapted from “Manipulating the mouse embryo-A laboratory manual”, Hogan et al., 1994
                      31
                                                                                                                                                       Gene Targeting   
Upon injection into a normal blastocyst though, ES cells retain their full 
developmental potential, contributing efficiently to both somatic and germ-line tissues 
(Bradley, 1984).  
A common strategy used nowadays to generate mutant mice strains involves the 
following steps, which will be subsequently discussed more in detail (FIG. 17):  
 
1. Construction of a targeting vector containing regions of identity with the mouse 
chromosome (homology arms), one or two selectable markers [generally a cassette 
that confers neomycin (G418) resistance] and planned modifications that ablate or 
alter the expression of the targeted gene. 
 
2. Introduction of the linearized targeting vector into mouse ES cells, derived from 
mouse strain A with coat color A [usually 129, therefore white or agouti 
(brown)], by electroporation (Thomas & Capecchi, 1987).  
 
3. Selection and screening by PCR and Southern for those rare targeted ES clones that 
have integrated the planned modifications by homologous recombination.  
 
4. Microinjection of targeted ES cells into host blastocysts obtained from mouse 
strain B with coat color B (e.g. C57BL/6, therefore black). The blastocysts then 
get re-implanted into the genital tract of a pseudopregnant mother and are allowed 
to grow to term. 
 
5. Among the offspring there will be so called chimeras, mice containing two 
populations of cells, namely those derived from the blastocyst (B) and those derived 
from the ES cells (A) and which can be easily spotted by the coat color as this will 
be a mixture of A and B.  
 
6. Crossing the chimeric mice with wild-type animals, and subsequent intercrossing of 
the heterozygous animals in the F1 generation finally leads to the generation of 
homozygous animals carrying the desired mutation in their genome. But this only 
happens in case the in vitro modified ES cells contributed to the germ-line of the 
chimeric animals. 
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Figure 17. Text on the following page.
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Isolation and Characterization of a genomic clone harboring the gene of interest that
is going to be mutated. 
3
Embryonic stem (ES) cells are obtained from 3.5 day pre-implantation embryos 
(blastocysts) collected frorm donor mice.  
2
Wild-type mice (+/+), having a coat colour referred to as coat colour A, are mated
and the female will be the donor of the pre-implantation embryo 3.5 days after
fertilization. In the example depicted here the coat colour is white as e.g. from 129
mice. 
1Construction of the TARGETING VECTOR- a piece of DNA that carries a gene or
DNA sequence of interest which has been modified and has integrated a positive (neo)
and a negative (tk) selection marker. In this case the positive selection marker has
substituted exon 2. More about selection markers see chapter 3.1. Among the offspring, chimeric animals are identified by coat colour, which will be a
mixture of the ES cell donors with coat colour A and blastocyst donors with coat
colour B. The mouse depicted here is strongly chimeric as most of its skin tissue is
derived from coat colour A. 
 Implantation of the blastocysts into a pseudopregnant foster mother.  
Injection of the targeted ES cells into the host blastocyst. In the illustration the
blastocyst is immobilized on a holding pipette (on the left) so that the inner cell mass
(ICM) is positioned on the far left-hand side of the embryo. The injection needle on
the right side is releasing the cells slowly into the blastocoel cavity. 
Wild-type animals (+/+) from another strain than the donor mice for ES cells are
mated to obtain blastocysts. In this case animals with black coat colour (referred to as
coat colour B) could be used, like e.g. C57 BL/6 mice. 
By extensive screening by PCR and/or Southern blotting the ES cell clones, in which
homologous recombination has taken place, are identified and the clones expanded. 
ES cells that successfully incorporated the construct are selected for with antibiotic
treatment, e.g. with G418 (neo) or gancyclovir (tk). 
The linearized targeting construct is introduced into wild-type ES cells by electro-
poration, a process that delivers an electric pulse to the cells and enhances absorption
of the construct across the cell membrane. Once inside ES cells, the construct can
undergo recombination with the intact genome, exchanging the construct’s DNA for
that of the native DNA in a specific region.  Chimeric mice, confirmed also as such by PCR and Southern, are crossed back to
wildtype mice. The offspring will be composed of mice having the same coat colour as
the ES cell donor (A) and mice having the same colour as the blastocyst donor (B). 50
% of the animals with colour A will be heterozygous for the mutated allele. These
germline chimeras are then interbred to generate homozygous mice (25 % of
offspring) 10               34
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3.1 Design of targeting vectors 
 
As the substrate for homologous recombination in a gene targeting experiment, a targeting 
vector should be designed in such a way that it recombines with a specific chromosomal 
locus in order to mutate it. Targeting vectors can be classified as replacement or insertion 
vectors, depending on their linearization and on the subsequent end result occurring by 
homologous recombination leading either to the replacement of the chromosomal target 
sequences with the vector sequences or to the duplication of the genomic sequences (FIG. 
18). The most frequently employed vector type to date, especially for the generation of null 



















Figure 18. Classification of targeting vectors. (A) Replacement type vector. In this example the targeting vector is 
designed so that the second exon of a target gene is disrupted by a positive selection cassette harbouring a neomycin 
resistance gene and a HSV thymidine kinase gene (tk) is positioned outside the area of homology. After homologous 
recombination (HR) with the linearized vector the tk is lost and in the targeted locus exon 2 has been replaced with neo. 
PCR primers P1 and P2 can be used to screen for HR. (B) Insertion type vector. The vector is linearized within th region 
of homology between exon2 and exon3 that carries a neo insertion as positive selection marker. HR leads to integration of 
vector sequences and partial duplication of genomic sequences. Thin lines represent plasmid backbone sequences; the 
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When designing a targeting vector, the following factors are essential to allow 
homologous recombination to occur with a specific chromosomal locus and to enable 
facilitated localization of the rare recombinant ES cell clones:  
 
1) arms of homology: these are sequences having the same nucleotide sequence as the 
desired chromosomal integration site. Targeting vectors generally contain a so-
called short and a long arm of homology flanking the mutated region. In general, 
recombination rates increase with the length of total homology to about 10 kb, the 
minimum length of the short arm of homology being about 0.5 kb (Deng and Capecchi, 
1992).  
 
2) Selectable marker: Most integrations of transfected DNA molecules into genomic 
DNA occur at a low frequency rate and will normally be random (illegitimate 
recombination).  As only a small portion of these integration events (0,1-10 %) may 
occur by homologous recombination at the desired chromosomal locus, in order to 
maximize selection for these homologously recombined ES cell clones, the 
targeting vectors should include positive and negative selection markers (Mansour et 
al., 1988). Selectable markers require a promoter that is active in ES cells and 
relatively position-independent. 
POSITIVE SELECTABLE MARKERS selectable with 
Neomycin aminoglycoside phosphotransferase (neo) G418 (geneticin) 
puromycin (puro) puromycin 
Hygromycin B phosphotransferase (hyg) hygromycin B 
 
The most commonly used positive selection markers mentioned above are encoded 
by bacterial genes and confer resistance to drugs, therefore allowing a facilitated 
selection for ES cell clones that have stably incorporated the targeting vector DNA, 
though irrespective of its integration site. In addition, the introduction of the 
hypoxanthin-phosphoribosyltransferase (HPRT) gene in ES cells deficient for 
HRPT can also be used as a positive selection marker and in this case transfectants 
then need to be screened in HAT-medium (Matzuk et al., 1992). 
 
NEGATIVE SELECTABLE MARKERS selectable with 
HSV-ThymidineKinase (TK) FIAU, gancyclovir 
diphteria toxin A (DT-A) - 
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While positive selection markers are normally inserted in the targeting vector in 
between the two arms of homology, negative expression cassettes are mostly 
positioned at one or both ends of the vector. The main difference between these two 
selection types lies in the fact that a positive marker, when expressed, simply 
confers drug resistance, whereas the expression of a negative marker leads to cell 
death and its presence is therefore not wanted in the final homologous recombined 
ES cell. Cells expressing e.g. HSV-TK in presence of the nucleoside analogue 
gancyclovir {or FIAU=[1-(2-deoxy-2-fluoro-b-D-arabino-furanosyl)-5-iodouracil]} 
phosphorylate the latter and convert it into a toxic derivative, which finally kills the 
cells. The combined positive-negative selection, combining the ability to both 
positively select for stable transfectants as well as negatively select against random 
integrants can enrich for targeted events by up to 10-fold. The selection marker 
cassette should be removed after homologous recombination because of possible 
interference with the expression of neighbouring genes. 
 
3) Sequence identity should be maintained since it has been reported that 
recombination rates increase with usage of isogenic vector DNA (te Riele et al., 1992). 
This means that the targeting vector should be constructed from a genomic clone of 
the same genetic background as the ES cells to be used. The genetic background of 
the majority of available ES cell lines is 129. 
 
4) Linearization of the targeting construct is important for obtaining homologous 
recombinants. A single cutting site should therefore be available or made available 
at a site in the backbone of the plasmid, not within the homologous region or area 
of interest. 
 
Typically the creation of a targeting vector nowadays requires screening of a genomic 
library to obtain the gene of interest followed by restriction mapping. To design a cloning 
strategy the restriction mapping is necessary, also if the sequence is already available, to 
confirm the size of restriction fragments that will be needed for the subsequent cloning and 
for finding a possible unique site that will be needed for the linearization of the vector prior 
to transfection into ES cells. The cloning strategy normally involves numerous cloning and 
subcloning steps (e.g. see chapter 7, FIG. 28.). 
Recently a new method for a much more rapid generation of gene-targeting vectors 
was reported (Cotta-de-Almeida et al., 2003). The basis of this technology is to utilize strains of 
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E.coli that can efficiently carry out homologous recombination between short terminal 
homology regions on a linear PCR-derived fragment and sequences on a recipient plasmid. 
This strategy has been referred to as recombineering (for recombinogenic engineering). It 
involves identification of the genomic gene sequence of interest from publicly available 
databases and purchasing of an E.coli clone containing a BAC encompassing these 
sequences. Then, with the appropriately constructed template vector and the essential 
recombination machinery, the use of homologous recombination in E.coli can be used to 
manipulate directly the gene of interest in the BAC, avoiding numerous subcloning steps. 
The manipulated sequence within the BAC is then finally removed by identifying flanking 
restriction sites from the published sequence and under antibiotic selection the targeting 
vector is generated. 
 
3.2 The Cre/loxP recombination system 
 
The Cre/loxP recombination system 
originates form the bacteriophage P1 and 
provides nowadays the basis for the most 
versatile and widely applied strategy to 
introduce non-selectable mutations. The 
38 kDa enzyme Cre (causes 
recombination) catalyses the site-specific 
recombination between 34 bp sequences 
referred to as loxP (locus of crossover (x) 
in P1). The loxP sequence consists of two 
13 bp inverted repeats interrupted by an 8 
bp nonpalindromic sequence, the so-called 
spacer, which dictates the orientation of 
the overall sequence (FIG. 19A). When 
two lox P sites are placed in the same 
orientation, and at least 82 bp apart, Cre 
excises the so called ‘floxed’ sequence 
placed between them, leaving one loxP site 
within the genome whereas the second loxP 
is found on the excised circularised 
                    Figure 19. The Cre/laxP recombination system and making
subtle mutations. (A) Structure of a loxP site (B) Cre-
mediated recombination reactions (C) Example of an intro-
duction of a point mutation and removal of selection markers
by Cre mediated recombination. Firstly, a replacement type
targeting vector is used to introduce a point mutation into exon
2 (white line and filled triangle).   38
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fragment. If the two sites are oppositely orientated, inversion of the intervening DNA 
occurs (19B). To catalyse a recombination, Cre itself is sufficient and does not require 
additional co-factors. Cre has been shown to work in vitro as well as in various cells and as 
Cre does not have any endogenous target sequences it is more than suitable to be used in 
other species. In FIG. 19C an introduction of a point mutation is depicted. First, a 
replacement type targeting vector (exlained in FIG. 18A) is designed and used to introduce 
a point mutation into exon 2 (point mutation characterized by a fine white line within the 
exon marked from above with a little black triangle). As negative and positive selection 
cassettes the Diphtheria toxin A fragment (DT-A) and a neo-tk cassette are used 
respectively. Upon homologous recombination the DT-A fragment is lost in those cells that 
have integrated the vector in the right position, whereas if it was randomly inserted the DT-
A will kill the cells. Secondly, selection markers flanked by loxP sites are removed by Cre 
mediated recombination in ES cells leaving one loxP site in the genome, clones that lost the 
TK gene can be enriched by their resistance to FIAU. 
An alternative recombination system used, though with lower efficiencies, is the 
Flp/Frt recombination system from yeast, which is essentially the eukaryotic homolog of 
the Cre/loxP system (Dymecki, 1996; Meyers et al., 1998). Flp, a 423 amino acid monomeric 
peptide is very similar to Cre in that it requires no cofactors, uses a phosphotyrosine 
intermediate for energy, and is relatively stable. FRT is also similar to loxP in that it is 
composed of three 13 bp repeats surrounding an 8 bp asymmetric spacer region. The 
asymmetric region dictates whether excision (same orientation) or inversion (inverted 
orientation) of an intervening DNA sequence occurs after recombination.  
 
3.3 Screening and isolation of recombinant ES cells  
 
Following linearization of the targeting vector and transfection into ES cells, e.g. by 
electroporation, ES cell clones that survive positive (and negative) selection are identified, 
their DNA isolated, and investigated for the presence of a specific recombined allele. 
Verification of correct targeting is done either by polymerase chain reaction (PCR) and 
Southern blotting or by Southern blotting alone. The PCR analysis has the advantage that it 
can be done with minimal expansion of clones saving culture time/resources and helping to 
preserve the totipotency of the ES cells. It is therefore much quicker and provides results 
faster. In addition screening by PCR narrows down the number of putative positive clones 
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that then subsequently should still be confirmed by Southern in order to rule out the 
possibility of aberrant recombination products. 
If one wants to employ a PCR/Southern screening, the targeting vector will need to 
contain a short and a long arm of homology. A short arm of homology is generally in the 
range of 0.5-2 kb in size in order to be still amplifiable by PCR and detectable on agarose 
gels, whereas the long arm is generally in the range of 4-8 kb depending on a number of 
variables such as e.g. availability of sequence. A PCR screen ideally employs a primer 
adjacent to the region of homology (outside the short arm) and a second within the novel 
sequence within the targeting construct, e.g. the selectable marker as the positive selection 
marker is generally inserted at an asymmetric location near the short arm of homology. In 
this way only in the case that the two primer sites are juxtaposed by homologous 
recombination the correctly sized PCR product will be generated. 
Southern blotting analysis of the structure of the locus usually employs probes 
inside (internal, e.g. in the selection cassette) and outside (external 5’ and 3’ primers to 
check that precise recombination has occurred in both arms) of the targeting vector to 
exclude clones with aberrant recombination products. Appropriate restriction digests have 
therefore to be performed that should lead to the generation of diagnostic restriction 
fragments created by homologous recombination that can be easily distinguished from the 
endogenous copies. 
 If one decides to use only Southern blotting for screening, the homologous DNA 
should be more equally distributed among the two vector arms as aberrant recombination 
products are found more frequently using short arms. 
 
3.4 Production of chimeric mice 
 
Following the identification of the correctly mutated, in vitro manipulated ES clone, the 
latter gets amplified/expanded and then injected into the blastocoel of 3,5-days old mouse-
embryos called blastocysts. Approximately 10-20 ES cells are injected per blastocyst. The 
manipulated blastocysts are then in turn implanted into the uterine horns of day-3 
pseudopregnant recipient foster mothers, which have been obtained by mating females with 
vasectomized males. Ideally ca.12-16 blastocysts are transferred to a single foster mother 
meaning 6-8 per uterine horn. 
Following blastocyst injection, ES cells become incorporated within the developing 
inner cell mass (ICM) of the host embryo and contribute to the development of the 
different embryonic lineages in competition with the host cells. Some ES cells will migrate 
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to the genital ridge and become germ cells.  And as germ cells are derived from the same 
cell lineage that gives rise to the skin (primitive ectoderm), ES cells that have become germ 
cells will also contribute to the coat colour. Therefore to identify easily animals that 
harbour both host and ES cell contributions (so-called chimeras) blastocysts and ES cells 
from different mouse strain background are used. For example: ES cell contribution from 
the commonly used agouti (brown) 129 strain is readily detected in chimeras on the black 
background of C57BL/6 because these animals are patchy with black and brown areas.  
And the probability of germ cells originating from the implanted ES cells can be roughly 
equated with the degree of chimerism, meaning that in the above mentioned example a 
chimera with a high proportion of brown fur will have a high probability of transmitting the 
targeted gene to its offspring.  
Alternatively to blastocyst injection in order to generate ES cell/embryo chimeras, 
ES cells can also be injected into morula-stage (8 cell stage; 3 day old) embryos, or 
aggregated with morulae after removing the zona pellucida. In addition also tetraploid 
embryos may be used for injection or aggregation to make ES cell derived foetuses (Plagge 
et al). 
Most of the 129 derived ES cell lines are male and therefore germ-line transmission 
is usually through male chimeras. To establish a new mouse strain with ES-cell genotype, 
male chimeric animals are bred with wild-type females. As the chimeric animal will have a 
similar degree of chimerism in every tissue including the gonads, two types of progeny will 
be generated, e.g. in the example mentioned above the mating of the chimera with a BL6 
wild-type mouse will give black animals with BL6 phenotype and agouti (brown) animals 
with the 129 component. 50 % of these agouti animals will carry the mutation (only one 
allele was targeted) that was originally generated in the ES cells and therefore serve as 
heterozygous founders for a new mouse line. Agoutis with one targeted allele (+/-) should 
be identified by PCR (tail biopsy) and mated with each other to produce wild-type (+/+), 
heterozygous (+/-) and homozygous (-/-) animals for initial phenotyping. 25 % of the 
offspring will finally be homozygous harbouring the desired mutation on both alleles. 
 
 
3.5 Conditional Gene Targeting 
In contrast to the “conventional” gene targeting, that leads to inactivation or modification 
of a gene in all tissues of the body from onset of development throughout the whole 
lifespan, the “conditional” gene targeting is a restricted gene modification in the mouse, 
which is limited to either certain cell types (tissue-specific), to only a portion of its lifetime 
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(temporally-specific) or both. Conditional gene targeting approaches are particularly useful 
in cases where complete gene inactivation has been shown to lead to a lethal or otherwise 
adverse phenotype that therefore impedes a detailed analysis. Moreover, tissue specific 
gene inactivation may define physiological roles of the gene product of a widely expressed 
gene in certain tissues, without compromising other functions in the organism.  
The currently favoured method for conditional gene targeting in mice is operating 
with the Cre/loxP system (FIG. 20). The Flp/FRT would be an alternative to this 
recombinase system, but as its temperature optimum is ca. 28 °C whereas the mouse body 
temperature lies around 39 °C, Cre recombinase with a temperature optimum of 37 °C is 
much more suitable and efficient.   
 
Figure 20. Conditional knockout strategies: generation of targeted mice. In the first step, three loxP sites are 
introduced by HR into silent regions (e.g. introns) of a target gene (in this case two loxP sites flank the neo-tk selection 
cassette, the third one is upstream of exon 1). Upon Cre-mediated recombination in ES cells and FIAU selection, two 
different genomic deletions (type I and II, type III is not viable in FIAU) are obtained, depending on the loxP sites used. 
Type I deletions may represent non-functional alleles, whereas mice solely harboring two loxP sites in silent regions (type 
II deletion) should display no phenotype. These mice may then be crossed to Cre transgenic mice and double transgenic 
mice will undergo Cre-mediated recombination. 
 
 
Utilization of the Cre/loxP system for conditional gene inactivation or modification in vivo 
involves two lines of mice:  
1) A mouse line that has been generated using ES cell technology and that should give 
mice with so-called floxed alleles in all cells (FIG. 20). These mice should be 
phenotypically normal because the loxP sites were initially inserted into introns 
where they theoretically shouldn’t affect gene function.  
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2) The second line of transgenic mice is normally generated by standard oocyte 
injection techniques. These mice express Cre under the control of a transgenic 
promoter.  
Mating these two mouse lines should result in Cre-mediated gene disruption only in those 










Figure 21. Cre/lox Mouse Breeding. Mice with the Cre protein expressing in a specific cell type are bred with mice that 
contain a target gene surrounded by loxP sites. When the mice are bred, the cells carrying Cre will cause those cells to 
lose the target gene. 
 
 
Alternatively to the use of Cre transgenic mice the Cre gene has recently been delivered to 
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4.1 General Chemicals 
Reagent         Supplier 
Acetic acid        Merck 
Activated CH Sepharose 4B      Pharmacia 
Acrylamide        Bio-Rad 
Agar         Gibco BRL 
Agarose        Progen 
Ammonium acetate       Fluka 
Ampicillin        Fisons 
Aprotinin        Boehringer 
Blocking Buffer       Roche 
Boric acid        Fluka 
Bromophenol blue       Ajax  
BSA (bovine serum albumin)      Fluka 
Centricon        Millipore 
Chloroform        Fluka 
Colcemid        Gibco BRL 
L-cysteine        Sigma 
DAPI (4’6’-diamidine-2’-phenylindole dihydrochloride)  Boehringer 
DMEM (Dulbecco’s Modified Eagle Medium)   Gibco BRL 
DMSO  (dimethylsulfoxide)      Fluka 
DTT (dithiothreitol)       Promega 
DNA Ladder: 
Marker II, Marker V and Marker VI    Roche 
ECL (enhanced chemiluminescence)     Amersham 
EDTA (ethylenediamine tetra-acetic acid)    Boehringer 
EtOH (ethanol)       Fluka 
Ethidiumbromide       Sigma 
FCS (fetal calf serum)       Gibco BRL 
Formalin (10%)       Merck 
Formaldehyde        Fluka 
Formamide        Merck 
G418         Gibco BRL   
L-Glutamine        Trace 
Glycerol        Fluka 
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Reagent         Supplier 
HBSS         Gibco BRL 
HCL (hydrochloric acid)      Fluka 
HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid) Boehringer 
H2O2 (Hydrogen peroxide)      Sigma 
Isopropanol        Merck 
KAc (potassium acetate)      Fluka 
Kanamycin (for BAC clones)      Sigma 
KCL (potassium chloride)      Sigma 
Klenow enzyme       Boehringer 
KLH (keyhole limpet hemocyanin)     Calbiochem 
N-Laurylsarcosyl       Roche 
β-Mercaptoethanol       Sigma 
Methanol        BDH 
MgCl2 (magnesium chloride)      Sigma 
Milk powder        Migros 
Mowiol        Calbiochem 
NaAc (sodium acetate)      Merck 
NaCl (sodium chloride)      Merck 
Na2HPO4  (Sodium hydrogen phosphate)    Fluka 
NaH2PO4 (Sodium dihydrogen orthophosphate)   Fluka   
NaOH (sodium hydroxide)      Merck 
Nonidet P-40        Sigma 
Normal Goat Serum       Vector Lab 
Papain         Sigma 
Paraformaldehyde       Fluka 
Paraffin        Fluka 
PBS (phosphate buffered saline)     Trace 
Penicillin        Trace 
Phenol         GibcoBRL 
PMSF (phenyl-methyl-sulfonyl-fluoride)    Boehringer 
Poly-L-Lysine solution      Sigma 
Proteinase K        Gibco BRL 
SDS (sodium dodecyl sulfate)     Eurobio 
Taq DNA polymerase       Invitrogene 
TEMED (N,N,N’,N’-Tetramethylethylenediamine)   Bio-Rad 
Tris (Tris (hydroxymethyl) aminomethane)    Sigma 
Triton X-100        Fluka 
Trypsin EDTA       Gibco BRL 
Tween-20        Sigma 
Vectashield        Vector Lab 
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[α-32P]dCTP (~3000 Ci/mmol) was obtained from Amersham as 10mCi/mL solutions. 
 
4.3 Restriction enzymes 
Restriction enzymes were purchased from Boehringer, New England Biolaboratories or 
Promega and used with supplied buffers according to recommended protocols.  
 
4.4 Bacterial strains and buffers 
Plasmid DNA was grown in the bacterial strain DH5α (Life Technologies). 
 
DIG-Buffer   0.1 M   Maleic acid (Fluka) 
    0.15 M NaCl 
    pH 7.5 
 
10x DNA Loading buffer 250 mg bromophenol blue (Roche) 
    in 33 ml 150 mM Tris pH 7.6 
    Add 60 ml glycerol and 7 ml H2O 
 
HTB      10 mM HEPES              0.477g 
(competent cells)  15 mM CaCl2 (Fluka)    0.441g 
250 mM KCl                3.728g 
dissolved in 150ml H2O and pH adjusted to 6.7 with KOH (4M). 
Then MnCl2 was added and dissolved  55mM MnCl2 1.384g 
volume adjusted to 200ml, filter-sterilized through a 0.45µm filter 
stored at 4°C 
 
LB-Medium   1 % (w/v) Bacto-tryptone (BD) 
    0.5 % (w/v) Bacto-Yeast extract (BD) 
    1% (w/v) NaCl    
    pH 7.0  
 
LB-Agar   LB-Medium + 20 /l agar 
 
PBS  bought as a ready to make mix, needed only resolving in 
water and autoclaving. 
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SDS-PAGE running buffer 10 g SDS 
    30.3 g Tris 
    144.1 g glycin  in 800ml H2O    adjust to 1 l 
 
SOB    20 g Bacto tryptone, (BD) 
(competent cells)           5 g Bacto yeast extract  (BD) 
             0.5 g NaCl  
dissolved in 950 ml H2O and 10ml 250mM KCl were added. pH was 
made up with NaOH to 7 and the volume adjusted to 1l. The medium 
was then aliquoted, autoclaved and cooled to 60°C before adding 
5ml sterile 2M MgCl2 
 
20x SSC   3 M NaCl 
    0.3M Na-citrate 
        pH 7.0 
    
TBE buffer   89mM Tris 
    89 mM Boric acid 





T7 primer TAATACGACTCACTATAGGG 
 
T3 primer ATTAACCCTCACTAAAG 
 
SP6 primer GATTTAGGTGACACTATAG 
  
mVHL primer  
 
cDNA primer 1 -5’    
     5´– ACC CGG ATC CAC CAT GCC CCG GAA GGC AGC CAG TCC AG –3´ 
 
 
cDNA primer 2 –3’ 
 
 
             5´– TCC AGA ATT CAC CTC AAG GCT CCT CTT CCA GGT GCT GA –3´ 
 
short form mVHL-5’  
     5´– CGG TGG ATC CAC CAT GGA GGC TGG GCG GCC GCG GCC GG –3´ 
  
Exon 1  
      5’ primer 5´– AAT GCC CCG GAA GGC AGC CAG TCC –3´ 
      3’ primer 5´– CTC GGT AGC TGT GGA TGC GGC GGC –3´ 
 
Exon 2 
      5’ primer 5´– CGA GGT CAT CTT TGG CTC TTC AGG –3´ 
     3’ primer 5´– ATA CAC TGG CAA TGT GAT GTT GGC –3´ 
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Exon 3  
       5’ primer 5´– TGT ATA CCC TGA AAG AGC GGT GCC –3´ 
      3’ primer 5´– GGA CTC CTT CAA GGC TCC TCT TCC –3´ 
 
 
KNOCKOUT PROJECT  
 
For sequencing the BAMHI-fragments containing the VHL exons: 
 
T7 term  GCT AGT TAT TGC TCA GCG G 
Cl 17 v/n NdeI       GTA CTA TCA GGT ATG TGT GG 
5-BAC    GTA CAT GAG TAC ACT TTA GT 
11Ex2     AAG GTG TGC ACC ACC ACA GC 
Ex1-4A    AGG TAG GTG GCT CGC GTG TC 
Ex1-4B    TCG CAA GCT GGA CGT GGG CG 
41103793      GAT GGG CTC TAT TAA TAA CG 
41017635     TTC ACC GAG CGC AGC ACC GG 
Ex2-5´     AGG ATG GAA TAA ACT GAT GC 
Ex2-3´     GGG CAA CGG CAC TCC TCT GG  
vEx3      TCA TAG TTT ACC CTC CAG TG 
nEx3    GGC TGA AGA GAC TGT AAA GG 
 
 
loxP oligos for designing of the 3rd loxP site: 
 
loxPfor  primer   5´-GAT CTA TAA CTT CGT ATA ATG TAT GCT ATA 
CGA AGT TAT ATC AAG CTT ATC GC-3´ 
 
loxPback primer  5´-GGC CGC GAT AAG CTT GAT ATA ACT TCG TAT 
AGC ATA CAT TAT ACG AAG TTA TA 
 
 
Nde-site (neo-tk cassette) 
 
  5´-Nde site primer  5´–TCG AGG TCG ACC ATA TGT GGC CGA G –3´ 
  3´-Nde site primer  5´–CGC TCG GCC ACA TAT GGT CGA CC –3´ 
 
Exon 2- orientation  
 
Orient-5 primer   5´–TCT CAG TAC CCA GGT CAG GC –3´ 
Orient-3´primer   5´–CGA GTC GCC ACC GTC GTC GG –3´ 
 
To check loxP orientation (in pET-17b-N/B-loxP) 
 
vHind-loxP primer  5´–GGC CGA AAA CAA GTG AGT AT –3´ 
nHind-loxP primer  5´–CCT GGG GAT TGT ACA CCT GA –3´ 
 
 
neo-tk primer (for sequencing) 
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  neo-tk middle primer  5´–GGC CGC GAG AAC GCG CAG CC –3´ 
 
  neo-tk3-A primer  5´– CAT AGC CAG GTC AAG CCG CT –3´ 
  neo-tk3-B primer  5´– ACG GTA TCG CCG CTC CCG AT –3´ 
 
neo-tk2-A primer  5´– CCA TGG GGG ACC CCG TCC CT –3´ 





primer 5´.1 5´–CAT CTC ATG TTC TCA TGG GC–3´ 
primer 5´.5 5´–GCA TTC AGG TAT AAT CCA CC–3´ 
3´-PROBE 
primer 3´.4 5´–GTG CCA CTG CGT CTG CCC–3´ 






Cre-primer1   5´– GCG GTC TGG CAG TAA AAA CTA TC –3´  
Cre-primer2   5´– GTG AAA CAG CAT TGC TGT CAC TT –3´ 
 
Il-2 primer1   5´– CTA GGC CAC AGA ATT GAA AGA TCT –3´ 
Il-2 primer2   5´– GTA GGT GGA AAT TCT AGC ATC ATC C –3´ 
 
VHLflox: 
C1 primer   5´– CAT GTG CCT GCA GAG ACC AG –3´ 
C2 primer   5´– CAC GCA TCC ACA TCA GGT G –3´ 
 
D3 primer   5´– GGA GTA GGA TAA GTC AGC TG –3´ 
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5.1 Plasmid DNA purification from bacteria 
 
The isolation of plasmid DNA from bacteria was performed using the NucleoBond PC Kit 
from Macherey-Nagel, according to manufacturer’s instructions:   
A bacterial culture was set up by inoculating 50 ml of LB medium (plus antibiotic) with a 
single colony from a freshly streaked plate or from a glycerol stock. After overnight 
shaking at 37 °C the saturated culture was centrifuged at 6.000 x g for 15 min at 4 °C. After 
discarding the supernatant the pellet was re-suspended in 4 ml buffer S1 (50 mM Tris-HCl, 
10 mM EDTA; pH 8.0) containing 100 µg/ml RNase A. 4 ml Buffer S2 (200 mM NaOH, 
1% SDS) were then added to the suspension to denature both the chromosomal and plasmid 
DNA. Following a short incubation of max. 5 minutes at room temperature (RT) addition 
of 4 ml buffer S3 (2.8 mM KAc, pH 5.1) neutralized the lysate and caused the formation of 
a precipitate containing chromosomal DNA and other cellular components. This incubation 
was carried out for 5 minutes on ice. The suspension was then filtered through NucleoBond 
filters pre-wetted with sterile deionized H2O and the cleared lysate applied onto an 
equilibrated column (equilibrated with 2.5 ml buffer N2 (100 mM Tris, 15% EtOH, 900 
mM KCl, 0,15% Triton X-100, pH 6.3)). Following washing of the column with 10 ml 
buffer N3 (100 mM Tris, 15% EtOH, 1.15 M KCl, pH 6.3) the plasmid DNA bound to the 
anion exchange resin was eventually eluted with 5 ml buffer N5 (100 mM Tris, 15% EtOH, 
1 M KCl, pH 8.5). 3.5 ml Isopropanol precipitated the eluted plasmid DNA and after 30 
minutes centrifugation at 15000 g at 4 °C the supernatant was discarded and the DNA 
pellet washed carefully with 70% EtOH. The pellet was then dried at room temperature and 
finally dissolved in 50 µl sterile deionized H2O. 
 
5.2 Enzymatic treatment of DNA 
 
Restriction digest: The typical restriction digest was performed in a final volume of 20 µl. 
The following volumes of reagents would be added to the reaction tube: 1 µg DNA 
(usually 1-5 µl), 1 µl 10x Restriction enzyme buffer, 1 µl restriction enzyme and sterile 
deionized H2O was used to fill up until 20 µl. 
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Dephosphorylation of 5´ends: In a total volume of 50 µl 44 µl DNA were supplemented 
with 5 µl 10x One-Phor-All-Plus Buffer (Pharmacia) and 1 µl of a 1:20 dilution of Alkaline 
Phosphatase (Calf Intestine Mucosa; Pharmacia). The reaction mix was incubated at 37 °C 
for 30 minutes, followed by an incubation to stop the enzymatic activity at 85 °C for 20 
minutes. The reaction mix was then filled up to 100 µl with sterile H2Odest and extracted 
with Phenol/Chloroform and once chloroform. Addition of 1/10 Vol. NaAc and 2 Vol 
EtOH and centrifugation at 14.000 rpm for 30 minutes at 4 °C precipitated the DNA that 
was then re-suspended in 20 µl H2O. 
Ligation: The ligation of DNA fragments was performed using the Rapid DNA Ligation 
Kit from Roche. The vector DNA and insert DNA was dissolved in thoroughly mixed and 
diluted 1x conc. DNA Dilution Buffer to a final volume of 10 µl. 10 µl T4 DNA Ligation 
buffer was added to the reaction vial and mixed thoroughly. Finally 1 µl of T4 DNA-
Ligase was added to the tube and after mixing the reaction was allowed to incubate for 5 
minutes at RT. The ligation mix was then used directly for the transformation of competent 
cells. 
 
5.3 Isolation of DNA from agarose gels 
 
DNA was isolated from agarose gels by use of the QIAquick Gel Extraction kit from 
Qiagen according to manufacturer’s instructions. 
 
5.4 Polymerase chain reaction (PCR) 
 
PCR's were mostly carried out using the Taq polymerase and additional buffers from 
Invitrogen. Each PCR reaction amounting up to a total volume of 20 µl contained: 1 µl 
each of the forward and the reverse primers (both 10 pmol; final conc. 0.5 µM), 2 µl 10x 
PCR buffer (200 mM Tris-HCl (pH 8.4), 500 mM KCl), 0.6 µl 50 mM MgCl2 (final conc. 
1.5 mM), 1 µl 1% W-1 to improve thermo-stability), 0.4 µl 10 mM dNTP mixture (final 
conc. 0.2 mM each), 0.2 µl of 5 units/µl Taq DNA Polymerase and 12,8 µl sterile ultra-
pure water to increase the reaction volume to 19 µl. 1 µl of DNA was pipetted to a PCR 
tube and the 19 µl mix added. After short mixing the amplification reactions were 
performed in a thermocycler. Negative controls in which H2Odest replaced the DNA were 
included in every series of reactions as well as positive controls as a guideline for the 
migration of the expected bands. Thermal cycling conditions were 94 °C for 3 minutes, 35 
cycles of 94° C for 20 seconds, primer annealing for 30 seconds at the described 
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temperatures, 72 °C for and a final 72 °C incubation for 10 minutes. PCR reactions were 
subsequently analyzed by agarose gel electrophoresis (different agarose concentrations 
(depending on expected product size) containing 0.5 g/ml ethidium bromide). Inclusion of 
appropriate molecular weight standards DNA Markers enabled sizing of PCR products. 
 
5.5 Reverse Transcriptase-PCR (RT-PCR) 
 
First strand cDNA synthesis was performed using SUPERSCRIPT II RNase H- Reverse 
Transcriptase from GibcoBRL for the RT-PCR. Reaction was set up following 
manufacturers instructions.   
 
5.6 DNA sequencing 
 
Initial sequencing was carried out at the FMI internal facility utilizing an ABI PRISM 377 
DNA sequencer. Microsynth, a company providing sequencing services, then carried on the 
sequencing. 
 
5.7 Construction of VHL-knockout-construct 
 
Generation of VHL construct 
The VHL targeting vector was designed with the aim of flanking exon 1 of the VHL gene 
with two loxP sites in order to create a ‘floxed’ VHL mouse strain in which exon 1 could 
be deleted by crossing this strain with a tissue-specific Cre-mouse. The targeting construct 
was composed of: a neo-IRES-tk selection cassette flanked by loxP sites, allowing positive 
and negative selection, two arms of homology (homologous to the targeted chromosomal 
VHL locus) and a single 3rd lox P inserted 3’ of exon 1.  
 
Generation of the backbone vector of the targeting construct containing the 5’ arm of 
homology: The 5 kb-BamHI fragment, containing exon 1 of VHL, was excised from pBS 
and ligated into the pET-16b vector digested with BamHI and Bgl II in order to delete one 
BamHI site. The clone confirmed to have the insert in the right orientation (as depicted in 
the scheme) was digested with Nde I and BamHI and the obtained fragment was ligated 
into a pET-17b vector in order to have a unique Hind III restriction site in the insert and not 
present in the vector any more (b). The pET-16b vector containing the short fragment of 
the BamHI/BglII-NdeI fragment was going to be the backbone in which the whole targeting 
construct would be constructed in in the end and provided the shorter arm of homology (a). 
                      52
                                                                                                                                                                  Methods                              
 3rd lox P site: By oligo annealing the 3rd lox P site was created flanked by a BglII and a 
NotI site and containing a HindIII site. This fragment was subcloned into pBSKS and 
excised again by digestion with Hind III (c). 
Insertion of the 3rd loxP site: Fragment (c) was cloned into the unique HindIII site of 
plasmid (b) and thereby the 3rd loxP site was introduced 3’ of exon 1 (d). By NdeI and 
BamHI digestion the NdeI-BamHI fragment, which now contained the additional loxP site, 
was reinserted into the original pET-16b construct (a) from where it hade been excised in 
the first place (e).  
Insertion of the 3 kb BamHI  fragment creating the second arm of homology 3’ of the 
3rd loxP site. Into this plasmid (e) the BamHI fragment harboring exon 2 was cloned (from 
pBS) (f).  
Insertion of the neo-tk selection cassette: The neo-tk cassette was excised from pBS, 
(this construct was a kind gift from Ulrich Mueller) flanked with NdeI sites, by oligo 
insertion and cloning into pET-28a (XhoI and NotI), and was then introduced into the 
unique NdeI site of (f) completing the targeting vector construct.  
The plasmid maps can be found in the appendix and the sequences of the inserted oligos 
under material-oligonucleotides. 
 
Mouse VHL full-length construct: Full length mVHL-cDNA was created by RT-PCR on 
RNA samples kindly provided by Anne-Isabelle Michou. The primers used for this purpose 
were cDNA primer 1 -5’ and cDNA primer 2 –3’ (see primer list in materials). 
 
5.8 Isolation of genomic DNA from ES cell clones 
 
Medium was aspirated from each tissue culture well of 24-well plates containing ES 
colonies grown to confluency. After washing once with PBS, 400 µl Lysis buffer (100 mM 
Tris pH 8.5, 5 mM EDTA, 0.2 % SDS, 200 mM NaCl) including 50 µg/ml Proteinase K 
were added to each well and the plates were then incubated in a 37 °C incubator over night. 
The cell-lysate of each well was then carefully transferred into eppendorff-tubes and 
extracted with 400 µl of a 1:1 mixture of Phenol/Chloroform. After mixing and 
centrifugation at 14000 rpm for 2 minutes the upper phase was transferred into a new tube 
and extracted with 400 µl Chloroform. After mixing and centrifugation at 14000 rpm for 10 
minutes the upper phase was again transferred into a new tube and 1 ml of 100 % EtOH 
was added. The DNA precipitated as a white pellet that after an additional centrifugation at 
14000 rpm for 10 minutes was washed once with 70 % EtOH, centrifuged again and then 
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left to dry for at least 5 hours to get rid of all the Ethanol. Subsequently the pellet was re-
suspended in 50 µl H2O and agitated on a shaker at 30 °C for 24 hours to help re-
dissolving. 20 µl (approximately 10 µg) of this DNA were then used for the digest. 
 
5.9 Isolation of genomic DNA from mouse tails 
 
DNA for PCR: 
0,5-1 cm of the tail of a mouse were cut and lysed immediately or frozen at –20 °C. To 
each tail tip 500 µl of DNA digestion buffer (50 mM Tris-HCl pH 8.0, 100 mM EDTA pH 
8.0, 100 mM NaCl, 1% SDS), supplemented with proteinase K at a final concentration of 
0.2 mg/ml, were added and the lysis was allowed to occur at 55 °C for 6-24 hours with 
gentle shaking. After a short centrifugation the supernatant was transferred into new tubes, 
diluted 1:50 with H2Odest and 1 µl was used in a PCR reaction. 
 
5.10 Southern blot analysis 
 
5.10.1 DOT-BLOT and radioactive Southern Blot 
 
Dot-Blot: After subcloning the BamHI-fragments of the BAC clones into the pBSKS-
vector, the colonies obtained after over night incubation at 37 oC on an agar plate with 
ampicillin (amp) selection, were striked onto two fresh agar-(amp)plates.  One of them had 
a Hybond nylon membrane on top of it soaked onto the agar and the other one served as 
‘master plate’ allowing the further usage of the later identified positive clones (and was 
kept at 4 oC after appropriate expansion of the colonies). After allowing the clones to grow 
overnight at 37 oC, the nylon membrane was carefully removed from the agar plate and 
incubated for 7 minutes in the denaturing solution (0.5 M NaOH, 1.5 M NaCl), followed by 
2x 3 minute-incubations in the neutralizing solution (0.5 M Tris pH 8.0, 1.5 M NaCl). 
After 5 minutes washing in 2x SSC the membrane was dried in 3MM paper (whatman) for 
10 minutes and UV-crosslinked with the stratagene transilluminator.  
 
BAC-clone Southern Blot: The DNA of the BAC clones was digested with the 
appropriate restriction enzyme(s) over night (where the enzyme was added at least twice as 
1 µl) and loaded on a 0.8 % agarose-gel. Following migration, the gel was stained 
subsequently with ethidiumbromide (0.5 µg/ µl) for 30 minutes and a picture was taken to 
asses proper digestion of the DNA. The DNA on the gel was then denatured by incubation 
of the gel for 45 minutes in denaturing solution (1.5 M NaCl, 0.5 M NaOH) under constant 
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gentle agitation. After shortly rinsing the gel in H2O, it was incubated for 2x 15 minutes in 
neutralizing buffer (1 M Tris pH 7.4, 1.5 M NaCl) and the incubated in 10x SSC for 30 
minutes, as was a nylon membrane. Capillary transfer of the DNA from the agarose gen 
onto the nylon membrane was allowed for at least 24 hours. Following transfer the 
membrane was marked and then washed in 5x SSC for 15 minutes before being subjected 
to UV-crosslinking by the stratagene transilluminator. 
 
Generation of Southern Probes – radioactive labeling: The probes utilized for screening 
the BAC-clones for the presence of the VHL gene were labeled with the random primed 
Megaprime DNA labeling kit: The DNA was denatured for 10 minutes at 100 oC and then 
cooled on ice. In a microfuge tube to 25 ng of this denatured DNA 3 µl of unlabeled 
dNTPs, 2 µl of the 10x reaction buffer and 5 µl of α32P-dCTP (= 50 µCi) were added and 
the reaction volume was increased to 19 µl by addition of H2O. Then 1 µl of Klenow 
enzyme was added and the whole reaction mixture was incubated for 10 minutes at 37 oC. 
The reaction was stopped by addition of 2 µl 2 M EDTA (pH 8.0) and additional heating to 
65 oC for 10 minutes. The specific activity of the probe was determined, and the probe was 
then subjected to a Nick-spin sepharose G-50 column (Pharmacia-Biotech) to eliminate 
unincorporated nucleotides. The specific activity was reassessed, to ensure that it didn’t get 
lost on the column, and if it didn’t drop below 106cpm, the probe was stored at –20 oC until 
further usage. 
 
Pre-hybridisation:  The membrane was incubated for 4 hours in 65oC pre-warmed Church 
& Gilbert (C&G) Hybridisation buffer (0.25 M Na2HPO4 pH 7.3, 1 % BSA, 1 mM EDTA 
pH 8.0, 7 % SDS – all sterile filtered). 
 
Hybridisation: 100µl of salmon sperm DNA (10mg/ml) and probe were both denatured by 
heating to 95 oC for 5 minutes before being mixed. This DNA-mixture was then added to 
15 ml of C&G buffer and incubated with the membrane at 65oC overnight. The membrane 
was then washed 4x 30 minutes at 65 oC with washing buffer (20 mM Na2HPO4 pH 7.3, 1 
mM EDTA pH 8.0, 1 % SDS) and then dried slightly between two whatman papers. Finally 
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5.10.2 Non-radioactive Southern Blot for genomic DNA (ES-cells or mouse tail) 
 
Generation of Southern Probes – DIG labeling: For the creation of a 5`-probe to test for 
homologous recombination primers 5`.1 and 5`.5  were used in a PCR reaction utilizing 
genomic wild-type DNA as template whereas for the creation of a 3´-probe primers 3.`4 
and 3.`6 were used. The bands corresponding the expected sizes were then isolated from an 
agarose gel and the purified DNA subjected to another PCR using the DIG labeling Kit 
from Roche. The 50 µl reaction contained 1x PCR buffer, 2 mM MgCl2, 2 µl primer.  
The following program was used: denaturation at 94 °C for 3 minutes, 35 cycles of 
denaturation at 95 °C for 20 seconds, annealing at 57 °C for 30 seconds and elongation at 
72 °C for 45 seconds. This was followed by incubation at 72 °C for 10 minutes. From the 
50 µl starting volume 5 µl were loaded on an agarose gel to check for PCR efficiency and 3 
µl were dissolved in 20 µl H2O, denatured for 5 minutes in a boiling water bath and placed 
on ice for 5 minutes before being added to 15 ml pre-warmed Pre-hybridisation (Pre-hyb) 
buffer.  
 
DNA-gel blot analysis: DNA was digested with the appropriate restriction enzymes in a 
reaction volume of 30 µl containing 3 µl buffer and 1 µl enzyme. The restriction digest was 
allowed to take place at 37 °C over a period of ca. 24 hours, during which two more 
additions of enzyme occurred. 5 µl loading dye were then added to the reactions and the 
DNA was resolved on 0.8 % agarose gels, which were run overnight at 40 V. A DIG-
labelled Marker II was used to enable sizing of the DNA fragments.  
The gels were then incubated in an ethidium bromide “bath” (0.5 µg/ml) with gentle 
agitation for half an hour, washed in H2Odest for 5-10 minutes and a picture was taken to 
see whether the digest had been successful. If so, the gels were incubated for 20 minutes in 
Denaturing buffer (1.5 M NaCl, 0.5 M NaOH) at RT and constant gentle agitation, 
followed by two 20 minutes-incubations in Neutralizing buffer (87.6 g NaCl, 60.8 g Tris, 
33 ml 37% HCl in 1 l H2O). DNA was then capillary transferred in 20x SSC to Zeta-Probe 
GT positively charged nylon membranes (Bio-Rad) and fixed by UV-crosslinking. 
 
Pre-hybridization was performed for 2 hours in 15 ml Pre-Hyb-buffer (for 30 ml: 15 ml 
Formamid, 7.5 ml 10x Blocking buffer (50 g powder in 500 ml DIG-Buffer), 7.5 ml 20x 
SSC, 300 µl 10 % N-Laurylsarcosyl, 60 µl 10 % SDS and 1 ml sonicated salmon sperm 
DNA (10 mg/ml)) at 42 °C. After addition of the denatured probe, hybridisation was 
performed overnight under the same conditions. The membranes were washed 
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consecutively in 2x SSC/0.1 % SDS (5 minutes, RT), in 0.5x SSC / 0.1 % SDS (20 
minutes, 68 °C) followed by 20 minutes at 68 °C in 0.1x SSC / 0.1 % SDS. Finally the 
blots were subjected to immunological detection using an anti-DIG antibody conjugated to 
alkaline phosphatase and the CDP-star kit from Roche Diagnostic, according to 
manufacturer’s instructions. 
 
5.11 Preparation of competent cells 
 
A 200 ml SOB medium culture inoculated with about ten large colonies from a freshly 
grown plate of DH5alpha was left to grow at 26 °C with vigorous shaking until reaching an 
OD600 of 0.45. The culture was then split into sterile centrifuge tubes (4x 50ml falcon 
tubes) and placed on ice for 10 minutes. After spinning for 15 minutes at 2500 g, the 
supernatant was discarded, the pellet re-suspended in 64 ml HTB (4x 16ml) and placed on 
ice for 10 minutes. After spinning and discarding the supernatant again the pellet was re-
suspended in 16 ml HTB (each pellet in 4 ml and then pooled). 1.2 ml filter-sterilized 
DMSO were added slowly while gently swirling the cell suspension and the cells were then 
immediately aliquoted into convenient aliquots (200 µl, 500 µl) and quick frozen by 
throwing into liquid nitrogen. Storage of competent cells occurred at –80 °C. 
In some exceptional cases XL10-Gold Ultracompetent cells from Stratagene were used 
according to the manufacturers transformation protocol. 
 
5.12 Transformation of E.coli 
 
100 µl of cold bacteria competent cells were added to the ligation mix or DNA and the 
whole reaction was incubated for 30 minutes on ice. After heat-shock for 2 minutes at 42 
°C, followed by 5 minutes incubation on ice, the transformed cells were spread on LB-
Agar plates containing the appropriate antibiotic. 
 
5.13 ES cell karyotype analysis 
 
ES cells were split onto a gelatine coated 10 cm dish the day before the analysis to ensure 
actively dividing cells. Fresh ES-medium was added 3 hours prior application of colcemid 
(10 µg/ ml; Gibco). After four to six hours incubation at 37 ˚C, the cells were washed once 
with PBS and trypsinized with 0.1 % trypsin for 3 minutes at 37 ˚C. 5 ml ES-medium were 
added to stop the reaction, followed by centrifugation at 900 rpm for 5 minutes. The 
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supernatant was removed and the cells were resuspended in 1 ml PBS. Cells were pelleted 
by centrifugation at 2000 rpm for 2 minutes. After removal of the supernatant the cells 
were carefully resuspended in 1 ml 0.56 % KCl and left standing at room temperature for 
10 minutes. After centrifugation at 2000 rpm for 2 minutes the pellet was resuspended 
slowly in ice-cold and freshly made fixative (methanol/ acetic acid 3:1). After incubation 
on ice for 10 minutes and short centrifugation the last step was repeated and the cells were 
let sit overnight at 4 ˚C. The next day after short centrifugation, the cells were resuspended 
again in 0.5 ml fixative. With the help of a Pasteur pipette the cells were dropped onto a 
clean microscopic slide from about 0.5-1 meter above and dried on a tray on top of a 37 ˚C 
water bath. The next day the cells were stained for 20-30 minutes in 3% Giemsa (in GuRR 
buffer) at room temperature. The slides were then washed briefly in water, air-dried at 
room temperature and coverslipped in entellan. The solutions like Giemsa, ES-medium and 
entellan were provided by the transgenic facility at the FMI. 
 
5.14 Primary antibodies 
 
The rabbit polyclonal antibody α-pVHLMm (CT) was raised against the synthetic peptide 
RKDIQRLSQEHLESQHLEEEP that corresponds to the carboxyl terminal amino acid 
sequence of the murine VHL protein. The peptide was coupled to keyhole limpet 
haemocyanin (KLH) (Pierce) by Glutaraldehyde (Serva, Heidelberg) coupling and injected 
into rabbits. Antiserum was obtained from Eurogentec (Bruxelles) and affinity purified 
over a column generated by coupling 10 µg of the peptide to 1 g of activated CH-
Sepharose 4B (Pharmacia) according to manufacturer’s protocol.  
Other antibodies used in the expression study were: rabbit polyclonal α-calbindin D-28k 
(Swant, Bellinzona, CH), mouse monoclonal α-Rho4D2 (kindly provided by Robert 
Molday, Vancouver, Canada), rabbit polyclonal α-p27 (C19) (Santa Cruz), rabbit 
polyclonal α-CRALBP (kindly provided by John Saari, Seattle, WA), mouse monoclonal 
α-GS (Chemicon, Temecula, CA), mouse monoclonal α-Vimentin (Chemicon, Temecula, 
CA) and rabbit polyclonal anti-RPE65 (kindly provided by Andreas Wenzel, Zürich, CH). 
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5.15 Cell culture 
 
Mouse NIH3T3 cells were maintained in Dulbecco´s modified Eagle´s Medium (DMEM, 
Invitrogene) supplemented with 5 % bovine calf serum (BCS), whereas the murine kidney 
tumor cell line RENCA was cultured in DMEM supplemented with 10 % fetal calf serum 
(FCS). Cultures were maintained at 37 °C in a humidified 95 % air and 5 % CO2 
atmosphere. 
 
5.16 Western Blot analysis 
 
For immunoblot analysis either postnatal P2 eyes from euthanized C57BL/6J mice were 
isolated, enucleated and the neural retina separated from the retinal pigment epithelium or 
alternatively NIH3T3 and Renca cells were harvested after being rinsed with phosphate 
buffered saline (PBS, Biochrom AG). Retinas or cells were homogenized through a G25 
syringe in lysis buffer (20 mM HEPES, 0.4 M NaCl, 25 % glycerol, 1 mM EDTA, 5 mM 
sodiumfluoride, 0.1 % Nonidet P-40, 100 µg/ml phenylmethylsulfonyl fluoride, 100 µg/ml 
aprotinin, 1 mM Dithiothreitol). After standing on ice for 30 minutes the cell lysates were 
cleared by centrifugation at 14.000 rpm at 4 °C for 10 minutes. Protein concentrations were 
measured using the BioRad Protein Assay (Bio-Rad Laboratories) and cell lysates 
containing equal amount of protein were resolved by electrophoresis on a 12 % 
polyacrylamide-SDS gel and electroblotted onto nitrocellulose membrane (Optitran BA-
S83, Schleicher&Schuell). After blocking in TBST buffer (50 mM Tris-HCl buffer, pH 8.0, 
containing 150 mM sodium chloride, 0.1 % Tween 20) with 5 % (w/v) nonfat dry milk, the 
membrane was incubated over night at 4 °C with α-pVHLMm (CT) diluted 1:500 in TBST 
+ 5 % milk. Washing of the membrane for 30 minutes at room temperature in TBST was 
followed by incubation with horseradish peroxidase-conjugated secondary antibody. The 
antigen-antibody complexes were detected using a chemiluminescence reagent kit (ECL 
Kit, Amersham Biosciences) according to manufacturer’s instructions. 
 
5.17 Preparation of murine tissues for immunohistochemical staining  
 
C57BL/6J mice were obtained from Charles River Laboratoires France. Experimental 
procedures were designed to conform to the cantonal guidelines. 
Eyes and cerebellum from euthanized C57BL/6J mice at various stages of development 
were used for immunohistochemical studies. Embryonic day E 0.5 was determined by the 
presence of a vaginal plug and the day of birth was designated as postnatal day P0. Tissues 
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were fixed overnight at 4 °C in 10 % formalin, embedded in Paraffin and sectioned at 5-20 
µm. 
 
5.18 Immunohistochemical studies 
 
Paraffin sections were subjected to de-paraffinization in xylene and subsequently ethanol 
series. After incubation in PBS (+ 0.3 % Triton X-100) for 20 minutes, sections were 
subjected for 10 minutes to 97 °C in 10 mM Citrate Buffer pH 6.0 for antigen retrieval and 
slides were then left to cool down by standing for at least 20 minutes at room temperature. 
Short incubation in PBS at RT was followed by incubation for 30 minutes in 3% H2O2 / 10 
% methanol to block endogenous peroxidases. After short washes in PBS sections were 
pre-incubated with 10 % normal goat serum (NGS; Vector Laboratories) in PBS (+ 0.3 % 
Triton X-100) for 30 minutes. Incubation with primary antibody was allowed over night at 
4 °C or for 2 hours at RT. For ABC stainings the α-pVHLMm (CT) antibody was diluted 
1:200, whereas for immunofluorescent studies all primary antibodies were diluted 1:50 in 
10 % NGS in PBS (+ 0.3 % Triton X-100), except α-Rho4D2 and α-calbindin that were 
diluted 1:100.  
a) ABC staining:  
After 3 washes of 5 minutes in PBS (+ 0.3 % Triton X-100) sections were 
incubated with biotinylated goat α-rabbit diluted 1:200 in 10 % NGS in PBS. 
Colometric detection using the ABC Elite Kit (Vector Laboratories) was performed 
according to manufacturer’s instructions. Slides were counterstained with 
hematoxylin and finally mounted using Mowiol. 
b) Immunofluorescent staining 
Sections were washed in PBS (+ 0.3 % Triton) and incubated for 1 hour at room 
temperature with FITC- or Cy5-labeled secondary antibodies. After shortly rinsing 
the slides in H2O, sections were coverslipped with Vectashield (Vector 
Laboratories). 
c) Immunofluorescent staining using TSA kit 
If two rabbit polyclonal antibodies were to be used in a co-staining experiment the 
Tyramide Signal Amplification Kit (TSA; Perkin Elmer) was used according to 
manufacturer’s protocol. 
We used either conventional or confocal fluorescence microscopy to view the slides. 
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5.19 BrdU labelling 
 
P7 mice were injected intraperitoneally with 100 µg BrdU / g body weight. Mice were 
sacrificed 2 hours later, their brains dissected, fixed in 10 % formalin and processed for 
paraffin sectioning. The in situ cell proliferation KIT, FLUOS (Roche) was used according 
to manufacturer’s protocol. 
 
5.20 Retinal Tissue dissociation 
To dissociate retinal tissue a protocol by Wahlin et al., 2004 was followed. In short: After 
euthanization of BL6 mice their eyes were enucleated and the neural retinae were isolated 
from the retinal pigment epithelium (RPE) in PBS without Ca2+ and Mg2+ at RT. The 
retinae were cut into smaller pieces and incubated in HBSS containing 1 mM EDTA and 5 
U / ml Papain, pre-activated with the reducing agent L-cysteine (2.7 mM) for 30 minutes at 
37 °C. For Müller glia cell isolation retinas were incubated for 15 minutes at room 
temperature followed by at least two washes with DMEM containing 10 % FCS. 
Dissociation of the tissue occurred by sequential trituration with Pasteur pipettes and the 
dissociated cells were then pelletted and resuspended in DMEM / 10% FCS. Dissociated 
cells were dropped onto polylysine-coated slides and incubated for a couple of minutes to 
allow attachment. Subsequently the cells were fixed with 4 % paraformaldehyde for 5 
minutes, gently washed in PBS and permeabilized for 20 minutes in PBS containing 0.3 % 
Triton X-100. After blocking with 10 % Normal Goat Serum in 0.3 % Triton X-100 in PBS 
incubation with the primary antibody was carried out overnight at 4 °C. Antibody dilutions 
were: anti-CRALBP 1:50, anti-calbindin 1:50, anti-Rho4D2, anti vimentin 1:50. After short 
washes in PBS secondary antibody incubation was allowed for 45 minutes at RT. The 
slides were then shortly rinsed and mounted with Vectashield. 
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Aim of this thesis 
 
 
The aim of this thesis was to obtain a detailed picture of VHL protein expression in 
primary VHL-disease target tissues, such as the retina and the cerebellum, in order to use 
this information to model VHL disease in mice and consequently attain a better 
understanding of its pathophysiology. 
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Homozygous disruption of VHL in mice resulted in embryonic lethality by embryonic day 
E 10.5-E 12.5 due to the absence of placental embryonic vasculogenesis and subsequent 
hemorrhage and necrosis (Gnarra et al., 1997). As this precluded the investigation of VHL 
function in the adult, we decided to use conditional gene targeting technology based on the 
Cre/loxP recombination system (see introduction chapter 3) to generate a conditional VHL 
knockout, a “floxed” VHL-mouse (overview FIG. 22). VHL could then be inactivated 
tissue-specifically by crosses of these floxed mice with Cre-mice.  
 
Figure 22. Overview of the strategy to 
produce a floxed VHL mouse or a 
complete VHL knockout.  From the top: 
The genomic locus illustrates the genomic 
organisation of the VHL gene to be floxed 
or deleted (in red exon 1). Below, the 
targeted genomic locus is depicted. In 
case of a homologous recombination 
event taking place the recombined 
targeted allele/locus will have the same 
structure as the targeting vector. The 
population of ES cells deriving from a 
clone harbouring a wt allele and a 
recombined allele, will then be transiently 
transfected with a Cre-expressing plasmid 
and clones will be selected with G418 
and/or gancyclovir.  The transfection will 
lead to three types of site-specific 
recombination. A) In this case exon 1 has been deleted but the selection cassette is still present. The ES cells containing 
this construct are not very useful as the selection cassette should be removed prior blastocyst injection, especially as the tk 
has been reported to cause male sterility if expressed in mice. B) This represents the ‘floxed’ allele or also called 2-lox 
allele as two lox P sites are still present, flanking exon1. This is the recombination event we were primarily interested in 
as mice homozygous for this allele could be crossed to tissue-specific Cre mice allowing the creation of a conditional 
VHL knockout. Therefore ES cells containing this allele would be used for blastocyst injection. C) ES cells containing the 
complete knockout, where the first exon has been deleted and the selection cassette is not present any longer would be 
suitable to create a complete knockout. The complete knockout, although already published, was still of interest to be 
created in a different strain background, as it has been shown that different mice strain backgrounds affect heavily the 
phenotype observed in knockout mice.  




1) Targeting vector design and cloning 
 
In order to design the cloning strategy for the creation of the VHL targeting vector the first 
step consisted in finding a genomic clone containing the whole gene of interest. Based on 
the information given about the mouse exon sequences of VHL (Gao et al., 1995; Gnarra et al., 
1997), primer pairs specific for exon 1 (oligos exon1-5’ and exon1-3’), exon 2 (oligos 
exon2-5’ and exon2-3’) or exon 3 (oligos exon3-5’ and exon3-3’) were ordered and tested 
for their efficiency to amplify the corresponding exon fragment from wild-type genomic 
DNA by polymerase chain reaction (PCR) (FIG. 23).  
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Figure 23. Testing PCR primers for specific
amplification of the three VHL exons. Primers
specific for exon 1, 2 or 3 of VHL were tested.
Lane 1 always shows the negative control, where
no template DNA was added to the PCR reaction,
whereas in lanes 2, 3 and 4 genomic DNA from
different sources (129, C57BL/6 and 129 derived
mouse strain respectively) was utilized. Marker VI
(M) was used as a size reference. For exon 1 a
fragment of 238 bp, for exon 2 123 bp and for
exon 3 201 bp were expected. The primer pair for
exon 1 always amplified two fragments, whereas
the primer pairs for exon 2 and 3 specifically
amplified the corresponding exon band, although
for the exon 3 primers occasionally also another
band appeared (not shown). 
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After identification of the exon 2-primer-pair as being the most efficient and 
specific one in amplifying the expected band of 123 bp, the primer pair together with the 
PCR protocol/conditions were sent to the company Incyte Genomics. There, this primer-
pair was utilized for a PCR screening of a 129 mouse-derived genomic library with the 
goal of identifying specific BAC (bacterial artificial chromosome) clones that harboured 
the complete VHL gene. As the VHL gene lies within a stretch of genomic DNA smaller 
than 12 kB, it was enough to screen with only one primer-pair assuming that in the case of 
a positive hit, the positive BAC clone, normally enclosing 120 kB of genomic sequence, 
would harbour the whole gene including also exons 1 and 3. 
In total three clones were obtained from the PCR screening and these were labelled 
with the numbers 361, 383 and 422 respectively. The next step comprised characterizing 
these clones and scanning them for the presence of the VHL gene. PCR analysis of the 
three BAC clones with the original primers used to amplify the three exons of VHL 








Figure 24. Confirmation by PCR of VHL
exon presence within BAC-clones. The
vector control, BAC clones 361, 383 and 422
and genomic DNA, as a positive control,
were tested for the presence of the VHL
exons.  Lanes 1, 2 and 3 represent PCRs with
primer-pairs specific for VHL exon 1, 2 and
3 respectively. In the genomic DNA control
as well as in all three BAC clones the
presence of all three exons of VHL was
confirmed. In the vector control a band for
the exon 1 primer-pair was detected that was
though lower than the expected size.   
Genomic  
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Physical mapping studies performed on the genomic clones obtained in the paper 
published by Gnarra in 1997 had shown that a digestion of these clones with BamHI gave 
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restriction fragments of 5 kb, 6 kb and 4 kb containing exons 1, 2 and 3, respectively. In 
addition a unique HindIII restriction site within the 6 kb-BamHI fragment of exon 2 was 
identified, whereas there were no HindIII sites within the other two BamHI-fragments 
containing either exon 1 or exon 3.  
In order to confirm the presence of these fragments in our case, the genomic DNAs 
of all three BAC clones were digested with BamHI alone or with BamHI and HindIII, and 
then subjected to Southern Blotting analysis by hybridization with a full-length mVHL-
cDNA-probe randomly labelled with α-32P-dCTP. As depicted in figure 25, the genomic 
BAC DNA, when digested using the BamHI restriction enzyme and hybridised with a full-
length mVHL-probe yielded 3 fragments/bands of 3, 4 and 5 kb instead of the expected 4, 5 
and 6 kb. When comparing the BamHI-restricted with the BamHI/HindIII restricted DNA 
the only striking difference was the disappearance of the 5 kb-band (9.6 kb band in case of 
clone 383) and the, as an alternative appearing smaller fragment of ca. 3.7 kb, which led to 
the assumption, always based on Gnarra’s paper, that the 5 kb-fragment could be the one 














Figure 25. Southern Blot of BAC-clones
confirming the presence of VHL exons and
defining their BamHI-fragment distribution.
Screening of a 129 mouse-derived genomic
library for BAC-clones harbouring the VHL
gene yielded the identification of three clones:
n. 361, 383 and 422. To confirm the presence of
the three VHL exons within these clones their
DNA was digested with BamHI (lanes a) and
BamHI / HindIII (lanes b) and subjected to
Southern Blot analysis with a full-length mVHL
cDNA probe (positive probe was on the same
gel, but not shown as fragment run much
lower). All three clones contained 3 BamHI-
fragments of ca. 5, 4 and 3 kb (except clone 383
that instead of the 5 kb fragment had a much
bigger sized fragment). Additional HindIII-
digestion only resulted in disappearance of the 5
kb-BamHI-fragment (or of the ca. 9.6 kb band
for clone 383) and in the appearance of a ca. 3.7
kb band. Subsequent labelling with an exon1-,
exon2- or exon3-probe allowed the association
of the BamHI-fragments with the corresponding
VHL-exons harboured within (Data not shown,
result just indicated by arrows). 
In order to link the three BamHI-fragments to the corresponding exon contained 
within, the southern blot was hybridised with specific probes for exon 1, exon 2 and 
eventually exon 3 (the probes were created by PCR on genomic DNA using the before 
mentioned specific primer-pairs) and the fragments were therefore identified as following: 
the 5kb-fragment contained exon 1, the 3kb-fragment exon 2 and the 4kb-fragment 
contained exon 3. The HindIII-site predicted to be in the BamHI-fragment containing exon 
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2 was not confirmed by our result, instead it was rather the BamHI-fragment harbouring 
exon 1 that had to contain such a restriction site. 
The BAC clone 361 was chosen to be digested with BamHI, the fragments between 
2,5-5,5 kb were extracted from the gel and subcloned into the Bluescript vector pBSKS. 
Single colonies were plated on a fresh plate and a Dot 
Blot was performed using the exon 1- or exon 2-specific 
probes to identify which clones had inserted the right 
fragments (FIG. 26).  
With this strategy we obtained 3 clones 
harbouring exon 1 in the Bluescript (pBSKS) vector, 3 
clones harbouring exon 3 and finally 2 clones harbouring 
exon 2 in the pBS-vector. All clones were confirmed by 
sequencing.  
In order to design the VHL targeting vector we 
had to first assemble the sequence of the VHL gene. As 
the whole sequence was not yet available, the clones had 
to be sequenced through completely to obtain all the information needed to design the 
cloning strategy (primers for sequencing see materials, chapter 4). In addition in silico analysis of 
the already known parts of the VHL gene locus was undertaken and compared with the 
sequenced DNA. When finally the whole sequence was deciphered, and all the possibly 
interesting restriction sites found, the design and subsequent cloning of the vector was 
initiated.  
Figure 26. Example of a dot blot.
After sub-cloning the 5 and the 4 kb
BamHI-fragments into pBS, the
colonies surviving ampicillin
selection were plated on a nylon
membrane and this one hybridized
with probes specific for exon 1, 2 or 3
in order to find positive clones
harbouring the different fragments.  
For the VHL targeting vector only the two BamHI-fragments containing exon 1 (5 
kb fragment) and exon 2 (3 kb 
fragment) were utilized (FIG. 27). 
A targeting cassette flanked by 
loxP sites, containing both a 
positive (neo) and a negative (tk) 
selection marker, was inserted into 
a unique NdeI-site approximately 
2.6 kb upstream of exon 1. A third, 
single loxP element was inserted 
into a HindIII-site lying 
downstream of exon 1. In order to 
Figure 27. Design of the targeting vector (below) in comparison
to the genomic locus of the VHL gene (top). In red are the two
arms of homology. B= BamHI restriction site. Further details see
text
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favour the homologous recombination event in the mouse, two arms of homology had to be 
present in the targeting vector. A shorter arm of homology of ca. 1.2 kb was provided 
nearby the positive/negative selection marker cassette and a longer arm of homology of ca. 
3.5 kb, containing also exon 2, was provided 3’ of the 3rd loxP site. The whole cloning 
strategy is depicted in figure 28 and is explained in more detail in the methods section in 
chapter 5.7. The final construct was confirmed by sequencing especially for checking the 










Figure 28. Schematic overview of the cloning steps involved for the creation of the VHL targeting vector. Details 




2) Electroporation of the targeting vector in ES cells and subsequent screening 
 
Prior transfection into embryonic stem (ES) cells, the vector was linearized by digesting the 
targeting vector (inside the pET-16b plasmid backbone) with the restriction enzyme ClaI, 
which only cut once, outside the construct, in the vector. ES cells were then electroporated 
to incorporate the targeting vector into the ES cell genome. The ES cell line used was 
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derived from a 129 mouse strain, which is characterized by the dominant brown (agouti) 
colour.  
The transfection of the targeting vector into ES cells and the subsequent selection 
with G418 (250 µg/ml) for ES-clones containing the neomycin-resistance gene were 
performed by Patrick Koop in the transgenic facility at the Friedrich Miescher Institute in 
Basel. G418 resistant clones were then picked and expanded to isolate enough genomic 
DNA to perform Southern analysis. 
With the aim of identifying the correctly recombined clones, three probes, which 
had been tested for their efficiency on wild-type genomic DNA before, were employed: 
two external, 5’ and 3’, probes and an internal neo-probe (kindly provided by Christiane 
Wirbelauer). The 3’-probe was used to confirm the proper insertion of the 3rd single loxP 
site by digestion of genomic DNA with NdeI and EcoRV, while the 5’ probe and the neo-
probe could both be employed on BclI digested DNA to screen for the presence of the 
selection cassette. As illustrated in figure 29 restriction digests of genomic DNA with 
EcoRV and NdeI and hybridisation with the 3’-probe were expected to generate a band of 


















 Figure 29. Southern Blot with the 3`-probe. A) Schematic diagram of the genomic locus of VHL and the relative 
position of the 3’-probe herein, depicted with red bar. B) The genomic VHL wt DNA, when restricted using EcoRV (E) 
and NdeI (N), was expected to generate a 9.1 kb fragment, whereas the targeted allele would in that case generate a 5.9 
kb fragment due to an additional EcoRV restriction site that had been introduced together with the 3rd loxP site. The 
restriction sites are shown as vertical red lines and the loxP sites as blue arrowheads. The neo-tk selection cassette is 
shown as a light blue box flanked by loxP sites (blue arrowheads).  In the depicted examples of southern blots all tested
clones contained the wt fragment, but only 3 clones were positive for the targeted allele fragment of 5.9 kb (clones 54,
60 and 117).  
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168 clones were digested with EcoRV and NdeI and hybridised with the 3’ probe. 
Among these, 4 clones, numbers 54, 60, 107 and 117, proved to have the right insertion of 
the 3rd single lox P in one of their two alleles. Only these four clones were expanded again 
and DNA was isolated in order to perform another southern to check with the 5’ and the 
neo-probe for proper insertion of the other elements of the targeting vector.  
Genomic DNA of the four clones that tested positive for the proper insertion of the 
3rd single loxP site was digested with BclI and subjected to southern blot analysis using 
first the 5’-probe and then the neo-probe. As depicted in figure 30 digest with BclI was 
expected to produce a 6 kb fragment for the wild-type allele and a 10 kb fragment for the 














Figure 30. Southern Blot with the 5`-probe. A) Schematic diagram of the genomic locus of VHL and the relative
position of the 5`-probe herein, depicted as red bar. B) The genomic VHL wt DNA, when restricted using BclI (B) was 
expected to generate a 6 kb fragment, whereas the targeted allele would in that case generate a 10 kb fragment due to the
insertion of the neo-tk selection cassette of about 4 kb in size. The restriction sites are shown as vertical red lines and the
loxP sites as blue arrowheads. The neo-tk selection cassette is shown as a light blue box flanked by loxP sites (blue
arrowheads).  In the depicted southern blot of the four clones, which had been positive for the insertion of the 3rd single 
lox P site, only two clones gave the expected fragment of the targeted allele (clones 60 and 117; control represents
genomic wt DNA). Strangely enough as this blot was hybridized with a neo-probe all four clones confirmed the 
presence of the neo-tk selection cassette as a 10 kb fragment (Data not shown). 
 
But in this case only two out of the four clones previously shown to be positive for 
the 3rd loxP site demonstrated the expected band of 10 kb. As the same blot could be 
hybridised with a neo-probe designed against the neomycin resistance gene in the neo-tk 
cassette, the presence of the selection cassette was though confirmed in all four clones with 
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this probe.  These contrasting results made us chose clone 117 for further experiments, as 
this was one of the two clones that had shown the expected fragment patterns in all 
southern blot proving that homologous recombination had occurred in this case. In addition 
the band detected by the neo-probe for the other positive clone, clone 60, had been much 
fainter, so that clone 117 in the end seemed to be the only appropriate one to pick as the 
basis for the next transfection round.  
The karyotype of the 117 ES cell clone population 
was investigated prior its utilization for the 2nd transfection 
as it is known that with time in culture abnormal variant 
cell clones can arise in ES cell populations. Among these 
some variants have an abnormal phenotype and may 
therefore be unable to contribute to germline transmission 
of genetic traits.  
The karyotype in this case was though proven to be 
acceptable, as 75 % out of 50 counted spreads didn`t show any karyotypic abnormalities. 




3) Transfection of the positive clone from 1. Electroporation with a Cre-
expressing plasmid and screening 
 
After expansion of clone 117, this ES-cell population was transiently transfected with a 
cytomegalovirus promoter-driven Cre recombinase plasmid (performed again by Patrick 
Koop at the Friedrich Miescher Institute). This time negative selection was provided by the 
presence of gancyclovir (2 µM) in the medium and cells expressing the thymidinkinase 
gene (present in the cassette together with the neomycin resistant gene) normally convert 
this nucleoside analog into a toxic derivative leading to their own death, therefore enriching 
for clones that have lost the selection cassette due to excision by Cre action. 
In total 168 surviving clones were picked and expanded, but unfortunately the DNA 
gained from the ES cells was not enough to perform southern blot analysis. Therefore a 
PCR screening strategy was utilized with the aim of identifying the putative positive 
clones, which would then have been subsequently re-grown in order to be confirmed by 
southern.   
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B)Figure 32. PCR screening strategy employed to identify clones containing either a floxed VHL allele or a VHL
null allele. A) Schematic diagram of the targeted allele and the relative position of the employed primers (depicted as
arrows) showing the orientation of the primers. B) The primer combination A.1 and C.2 depicted only in A) was used to
select for clones that did not contain the neo-tk cassette any longer and where therefore no band was detectable by PCR.
These clones were subsequently tested with all the primer sets listed in the table. On the left of the table the possible
allele structures are depicted  (although the second and fourth from the top should in theory not be present any more due
to the selection with the A.1 and C.2 primer in the beginning that was thought to ensure the absence of the selection
cassette). The fragment sizes expected with the primer pairs depicted on top of the table are shown for every possible
allele structure. Little stars mark the cases where the primers would have recognized the corresponding DNA, but where
the fragments were too big to be synthesized by PCR.  
All the clones were first tested for the presence of the neo-tk cassette with the 
primer pair A.1 and C.2 that could only give a band in case the cassette was still in one of 
the two alleles. With this screening approach out of the 168 screened clones the following 
numbers did not test positive and were therefore likely to have lost the selection cassette: n. 
4, 7, 8, 9, 18, 23, 29, 30, 31, 43, 47, 63, 85, 92, 121, 124, 137, 144 and 166. The high 
number of clones that still seemed to contain the neo-tk cassette led to the assumption that 
the gancyclovir selection hadn’t been very efficient, nevertheless we continued screening 
the above-mentioned clones for both the floxed and the complete knockout on one allele.  
Before screening these clones though, clone 117 was re-tested with this PCR 
screening also to ensure the usefulness of the strategy.  As shown in figure 33 clone 117, 
the clone that was chosen from the 1st transfection to be transfected with the Cre-plasmid, 
when compared to genomic wild-type DNA and screened with different primer sets 
confirmed the presence of the neo-tk cassette and the 3rd lox P site.   
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Figure 33. PCR screening strategy employed to identify clones containing either a floxed VHL allele or a VHL
null allele. A) ES cell clone 117 (from first transfection) was tested with different primer combinations for the Presence
of the neo-tk cassette and the 3rd lox P site (defined here as 2. loxP. The two loxPs refer to the floxed allele that we
wanted to screen for, therefore the primer pairs were utilized to screen for the presence of the first (1. loxP) or the
second loxP (2. loxP)). As control wt genomic DNA was utilized to prove efficiency of the selected primers. Clone 117
showed all the expected fragment sizes (the lower and fainted band in the C.1 + C.4 lane was not reproducible in other
experiments and is therefore neglected) and was therefore re-confirmed as a clone in which homologous recombination
had taken place. B) Clone n. 47 showed the fragments or absence of fragments defining it as a possible candidate for a
complete knockout, where VHL exon 1 had been excised leaving only a single loxP. Clone 8 is depicted as an example
of many clones that didn’t show any clear result as they had been negative for the presence of the neo-tk cassette but for
the rest behaved as if they contained the selection cassette.  
 
Among the clones obtained from the 2nd transfection there were four clones (n. 47, 
121, 137 and 166) that seemed to have a complete knockout (where exon 1 was excised 
and only a single lox P site left) on one allele (always remember that only one allele is 
recombined or ‘targeted’, while the other one remains WT). Unfortunately no clear 
“conditional “ clones, containing a floxed and a wt allele, could be identified, as the 
remaining clones showed abnormal PCR patterns. 
Nevertheless 12 clones of the originally 168 were re-grown and subjected to 
southern blot analysis. The DNA was digested with EcoRV and then hybridised with the 5’-
probe already used for the screening of the first transfection. Figure 34 illustrates the 









Figure 34. Southern Blot strategy testing the outcome of the 2nd transfection. The EcoRV restriction sites are depicted 
as vertical red lines and the 5’-probe is depicted as a blue bar.  
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The Southern Blot didn’t give any 6.1 kb band expected in the case of a recombined 
‘floxed’ allele, but the wild-type band expected to run above 20 kb could be seen for all 
clones confirming that the southern blot per se had worked. This result excluded the 
possibility of a floxed VHL gene within the selected clones, but didn’t eliminate the 
possibility of a complete knockout, where exon 1 had been deleted. 
In order to screen for a complete knockout, the DNA was digested with the BclI 
restriction enzyme and a VHL exon1-specific probe (used for screening the BAC clones in 
the beginning of this study) was utilized.  As depicted in figure 35, digestion with BclI was 
expected to generate a fragment of 6 kb for the wild-type allele and a 3.3 kb fragment for 
the complete knockout allele. The result of the southern blot confirmed the presence of 
three clones that had excised exon 1 and that were therefore complete knockouts 
(heterozygous though).  
Figure 35. Southern Blot testing for
complete knockout ES cell clones. The
digest with BclI was expected to create a 6
kb fragment for the wt allele (see also
figure 30). In the case of a VHL knockout
allele, where exon 1 had been excised by
Cre, a 3.3 kb fragment was expected.
Among the 12 tested clones (cl.) three
showed a strong (cl. 137) or faint (cl. 47
and 166) 3.3 kb band in addition to the wt
allele band.  
 
cl.     7    8      9    43  47   62   63  85  121 137 144 166  old
6 kb
3.3 kb
The main aim of this project had been to create a conditional knockout as it had 
been shown that the complete knockout was lethal. Although it would have been interesting 
to knock out VHL in another mouse strain due to the fact that it is known that the 
background affects the different outcome of a knockout, it was still more interesting and 
challenging to create a conditional knockout, so another attempt was undertaken. 
 
 
4) Re-Transfection of the positive clone from 1. Electroporation with a Cre 
expressing plasmid and screening  
 
After expansion of clone 117, that had been tested positive for the homologous 
recombination event in the first place (see 3)), another transfection with the Cre-plasmid 
was carried out. This time instead of gancyclovir selection, that hadn’t seemed to be very 
efficient in the first try, selection was carried out with G418. As opposed to the screening 
after the 1st transfection (of the targeting vector into the ES cells) in this case cells that 
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were dying were screened, as these had lost the selection cassette and were therefore the 
interesting ones. 
67 clones died during G418 selection and, as it was not possible to re-grow all of 
them, only 12 clones were chosen to be re-grown and tested by Southern.   
The southern strategy was the same one already explained before under point 4) and 
as a control DNA from clone 117 was utilized (FIG. 36).  
A) B) 
    1         4          9         12        15       21       43  
            2         5         10        13       1 9     23         117 cl.
   
    cl. 
    1         4         9        12       15       21       43  
         2         5        10       13       1 9     23      117
   4.5 kb
> 20 kb
Figure 36. Southern Blots of 12 clones that were supposed to have lost the neo-tk cassette. A) Southern blot with
the 5’-probe following EcoRV digestion was expected to give a 20 kb fragment for the wt allele and a 6.1 kb fragment
for the floxed VHL allele. The 117 ES cell clone (in red) was utilized as negative control, as this still retained the neo-
tk cassette and gave a 4.5 kb fragment (see also figure 34). Clone 43 came from the previous transfection round which
had given only complete knockout clones. None of the tested clones showed a fragment of 6.1 kb. B) The same blot
was tested for the presence of the neo-tk cassette with a neo-probe. Although the clones had been selected for their
inability to survive selection with G418 the hybridization with the neo-probe revealed that all clones except one
(cl.23) gave bands of a specific size. In addition clone 117, on which the 2nd transfection was based on, gave multiple
bands that were not explicable. 
 
As shown in figure 36A the wt band of  >20 kb could be seen for all twelve clones, 
whereas there was no clone that showed a fragment of 6.1 kb. While clone 117 contained a 
second fragment of the expected size of 4.5 kb, some of the other clones showed multiple 
faint bands. Testing of these clones for the neo-probe gave even more incomprehensible 
bands (FIG. 36B). In addition also clone 117, on which this second transfection was based 
on, started to show a strange band pattern putting everything in question that had been done 
until that moment. As, on top of everything, the conditonal knockout had been published in 
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 VHL gene expression studies on human fetal and adult tissues showed VHL mRNA to be 
ubiquitously detectable. Expression was not restricted to specific areas known to undergo 
abnormal differentiation as part of the VHL syndrome such as kidney, cerebellum and 
pancreas, but it was also present, among others, in the heart, lung and prostate. In addition 
VHL gene expression was evident in all derivatives of the three germ cell layers also 
during mouse embryogenesis, being most prominent in epithelial components of the lung, 
kidney and eye (Richards et al., 1996; Kessler et al., 1995).  
Expression studies of the VHL protein (pVHL) utilizing poly- and monoclonal 
antibodies against human VHL revealed wide cytoplasmic expression in human adult 
tissues (Sakashita et al., 1999; Corless et al., 1997; Los et al., 1995). However, despite the emergence 
of data on overall Vhl gene expression and elucidation of VHL function, little was known 
about the detailed VHL protein expression in the retina and cerebellum.  
To investigate pVHL expression during murine development and adulthood a 
mouse pVHL-specific antibody was raised and utilized in a detailed immunohistochemical 
study focusing on the development of two tissues that play a very important role in the 
course of VHL disease, namely the retina and cerebellum. 
 
1) Characterization of the α-pVHLMm (CT) – antibody 
 
Polyclonal rabbit serum was raised against the synthetic 21mer peptide corresponding to 
the C-terminus of murine pVHL. In order to test for the specificity of this antibody, defined 
as α-pVHLMm (CT), cell lysates of mouse NIH3T3 and Renca cells were prepared, loaded 
onto a 12% SDS-gel and subjected to immunoblotting. As illustrated in figure 37A the 
affinity-purified α-pVHLMm (CT) antibody recognized exclusively two endogenous 
proteins of expected molecular weights, 21 and 25kD. The abundance of the endogenously 
detected proteins was significantly increased in whole cell lysates prepared from cells 
previously transfected with a mammalian expression plasmid encoding either the long or 
the short form of pVhlMm. Thus the migration of the endogenous proteins is consistent with 
the one of over-expressed proteins (data not shown) and the antibody proves to be specific 
for murine Vhl. 
As in human, the mouse Vhl gene also encodes two proteins, termed pVHL21 and 
pVHL25, arising from two alternative start codons. The primary sequence in this case only 
differs by the additional presence of a single acidic repeat unique to the longer VHL 
protein, pVHL25. The mouse pVHL shares high homology with the human pVHL, sharing 
a 90% identity in the amino acid sequence in the middle part harboring the most important 
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sites. As the α-pVHLMm (CT) antibody recognizes both forms equally, no distinction 
between the forms will be made and both forms will be subsumed under the term “pVHL”. 
To study pVHL expression during development mouse embryos were euthanized, 
fixed in 10% formalin and embedded into paraffin. Sections were then stained with the α-
pVHLMm (CT)-antibody. Immunohistochemical staining of murine tissues from E17.5 
using α-pVHLMm (CT) revealed strong VHL expression in a variety of tissues. 
Representative examples of pVHL staining in tissues such as pancreas, lung and ear as well 
as in the retina are illustrated in figure 37B (a,d,g) and Fig. 37C (left panel). These findings 
correlate with the impressive Vhl expression pattern noted in Kesslers paper where e.g. at 
E16.5 the inner and outer neuroblastic layers of the retina revealed strong VHL mRNA 
expression activity. Moreover as shown previously for VHL mRNA, pVHL expression was 
not exclusively present in tissues known to be at risk in VHL disease development, but also 
in tissues not connected to the known VHL phenotypes.  
To document the specificity of the Vhl staining, the antibody was pre-incubated 
with an excess of peptide before use in immunostaining. As illustrated in Figure 37B 
(b,e,h) and 37C (right panel) the pre-incubation with the CT-peptide, which was  originally 
used to create the antibody, reduced the staining dramatically whereas incubation with a 
control peptide mimicking the N-terminus of Vhl didn’t affect the staining at all (Fig 37B 
right panels).  
pVHL expression in the retina was additionally confirmed by western blot. Whole 
cell extracts of retinas from P2 mice were resolved by electrophoresis on a 12 % 
polyacrylamide-SDS gel and electroblotted onto nitrocellulose membrane. Incubation of 
the membrane with α-pVHLMm (CT) revealed exclusively two bands migrating at the same 
size of the above characterized pVHL bands in NIH3T3 whole cell extracts. In this 
experiment expression of the longer pVHL form, pVHL25 seemed to be more prominent 
than the expression of the so-called shorter form, pVHL21. This difference in expression 
levels has been seen reproducible and will be interesting to be investigated in more detail in 
future. 
 
In conclusion these data show that α-pVHLMm (CT) is a highly specific antibody 
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Figure 37. Antibody characterization of the α-pVHLMm (CT) antibody.  
(A) Whole cell lysates of NIH3T3 (lane 1) and Renca (lane 2) cells were subjected to immunoblotting utilizing the α-
VHLMm (CT) antibody. In both mouse cell lines the antibody specifically recognized the endogenous expression of
two pVHL (Mm) forms defined as pVHL21 and pVHL25 (indicated by arrows). The migration of the detected
endogenous bands was confirmed by overexpression of the Vhl proteins in transfection experiments (data not shown).
(B) At E17.5 pVHL expression was detectable among others in the ear, pancreas and lung (a, d, g). Pre-absorption of
the α-pVHLMm (CT) antibody with the CT-peptide (1mg/ml), which was originally used to create this antibody,
showed strong competition of the signal (b, e and h), whereas pre-absorption with an NT-peptide as a negative control
showed no competition (c, f and i).  
(C) Strong pVHL expression at E17.5 was also detectable in the retina (left panel), where the signal could be
abolished completely by pre-absorption of the antibody with the CT-peptide (1mg/ml) (right panel).  
(D) pVHL expression in the retina was further confirmed by western blot in retinal whole cell extracts (lane 2). The
shorter pVHL form (21kD) seemed less abundant than the longer form (25kD) in comparison to NIH3T3 whole cell
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2) Localization of VHL expression during murine developmental and adult 
retina 
 
To determine pVhl expression at specific developmental stages during murine retinal 
development retinae from E10.5, E12.5, E14.5, E17.5, P0, P4, P8, P11, P16, P18 and adult 
animals were isolated, fixed in 10 % formalin, embedded in paraffin and sectioned at 
12µm. Postnatal stages P0, P4, P11, P16 and adult are represented in figure 38. In the left 
panels negative controls omitting the primary antibody are shown, whereas on the right 
side sections stained with α-pVHLMm (CT) can be seen.  
pVHL expression 
was detectable throughout 
development, from early 
embryonic stages on until 
adulthood. During postnatal 
development the overall 
pVHL-staining in the retina 
started to delineate a more 
pronounced pattern that 
could be already noticed by 
P4.  In adult animals pVHL 
localized to a defined 













Figure 38.  Localization of pVHL
expression in the developing
mouse retina. Mouse retina
sections of different developmental
time points (P0, P4, P11, P16 and
adult) were counterstained with
hematoxylin in the presence (right
panels, right row) or absence (left
panels, left row; CONTROL) of the
primary α-pVHLMm (CT) antibody.
A strong VHL signal was detected
throughout development and in
adulthood. Scale bars are indicated. 
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To find out which specific cells towards the end of retinal development were 
expressing pVHL to such a high level, we performed immunofluorescence stainings on 
paraffin sections utilizing cell-specific markers (FIG. 39). At first strong pVhl expression 
was re-confirmed throughout development as shown at E17.5 (b) and P16 (c) [negative 
control with no primary antibody seen in (a)]. Utilizing a Rod specific marker, α-Rho4D2 
(e), did not show any co-localization with the α-pVHLMm (CT) (d) to the same set of cells 
(f) as did not markers for retinal pigment epithelium, amacrine cells, horizontal cells and 
bipolar cell (data not shown). Strong co-localization was though found with a monoclonal 
antibody against Glutamine synthetase, α-GS, a known marker for müller glial cells (g-i) 
and even further confirmed with another müller glia cell marker, namely α-CRALBP (k), 
that also co-localized with α-pVHLMm (CT)(j) to the same cells (l).  
Figure 39. Immunofluorescent analysis of pVHL expression in the mouse retina by use of cell-specific markers.  
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Mouse retina sections were stained with α-pVHLMm (CT) antibody and cell specific marker antibodies. (a- c) Immuno-
staining utilizing a FITC-conjugated secondary antibody in the presence or absence (a) of α-pVHLMm (CT) as primary 
antibody confirmed strong pVhl expression in the retina as shown at E17.5 (b) and at P16 (c). (d-f) Co-staining of P9 
retinae with α-pVHLMm (CT) (d) and α-Rho4D2, a rod-specific marker (e) revealed no colocalization (f). (g-h) Co-
staining of P7 retinae with α-pVHLMm (CT) (g) and α-GS, a Müller glial cell-specific marker (h) revealed strong co-
localization (i). (j-l) Vhl immunostaining at P12 (j) also coincides with another Müller glial cell marker, namely α-
CRALBP(k), and confirms herewith its localization to this specific cell type. For all the shown stainings FITC- (GREEN) 
or Cy5-(RED) coupled secondary antibodies were used. Scale bar represents 50µm. 
 
To confirm and further analyze the subcellular distribution of pVHL localization to 
Müller glial cells and to investigate whether additional cells also expressed pVHL, we 
isolated retinal cells from adult mice and stained the dissociated cells with α-pVHLMm 
(CT) (FIG. 40). Also in this case strong pVHL expression could be noticed in specific cells 
(a,c,h) identifiable as Müller glia both by morphology (b,f) and by the use of two marker 
antibodies, α-GS (d) and α-Vimentin (i) that co-localized with α-pVHLMm (CT) (e and j 
respectively). Strikingly among these dissociated retinal cells another cell type was stained 


















Figure 40. pVHL is expressed predominantly in Müller glial cells, but also in another cell type. Dissociated retinal 
cells from adult mice were stained with α-pVHLMm (CT) and cell type specific markers. For all the shown stainings 
FITC- (GREEN) and/or Cy5-(RED) coupled secondary antibodies were used. pVhl expression localizes to specific cells 
(a,c,h) identifiable as Müller glia both by morphology (b,f) and by the use of two marker antibodies, α-GS (d) and α-
Vimentin (i) that co-localize with α-pVHLMm (CT) (e and j respectively) to the same cell. In addition another cell type 
stained for α-pVHLMm (CT) (k,m) that did not stain for the Müller glial cell marker vimentin (l,m). Sections were 
counterstained with DAPI, shown in dark blue, to highlight position of nuclei. Scale bar represents 10 µm. 
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We conclude that pVhl is expressed in the murine retina throughout development 
and that at the later stages of development it localizes predominantly to Müller glial cells 
and to another yet-to-be-identified cell type. In addition we observed that pVHL expression 
in these cell types appears to be exclusively cytoplasmic. 
 
3) Localization of VHL expression during murine cerebellar development 
 
To investigate pVhl expression during murine cerebellar 
development, cerebella (FIG. 41) from P0, P7, P12, P16, P18, 
P21 and adult animals were isolated, fixed in 10 % formalin, 
embedded in paraffin, sectioned at 12 µm, stained with α-
pVHLMm (CT) and analyzed both by immunofluorescence 
utilizing FITC-conjugated secondary antibodies as well as by 
DAB staining. Postnatal development of the murine cerebellum revealed a particular pVHL 
expression that was confined predominantly to the outer parts of the cerebellar cortex 
(FIG.42, see white arrows).  
Cerebellum








Figure 42. Localization of Vhl
protein during postnatal
development of the cerebellum.  
12 µm thick sagittal sections of
murine cerebella from P7, P12 and
P16 were stained with α-pVHLMm
(CT) and analyzed both by
immunofluorescence utilizing
FITC-conjugated secondary
antibodies (left panels) as well as
by DAB staining counterstained
with hematoxylin (high
magnification view, right side).
pVHL expression was confined
predominantly to the outer parts of
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The adult peripheral cerebellar cortex contains two principal neuronal subtypes, 
namely the Purkinje cells and the granule cells constituting the internal granular cell layer 
(IGL). The granule cells are derived from peripherally located mitotic or “cycling” cells in 
the external germinal layer (EGL) which after birth exit cell cycle, start differentiating and 
migrating along radial glia across the Purkinje cell layer to then settle and constitute the 
IGL. The inward migration of EGL cells continues approximately until P15 when the EGL 
disappears. The observed pVHL expression was localized to the molecular layer area and 
the EGL throughout development as specifically noticeable by P16 when only a thin stretch 
of VHL staining can be noticed on the very edge of the cerebellar foliae coinciding with the 
fact that by this developmental stage the EGL disappears. 
The fact that pVHL has been shown to be expressed in CNS neuronal cell 
precursors and the specific change in position of Vhl expressing cells during cerebellar 
development made 
an involvement of 
progenitor cells 










igure 43. pVHL expression in the External Granular layer (EGL). Sagittal cerebellar sections were stained with α-









subsequent staining for an BrdU antibody (a). Additional staining with α-p27 (b) confines p27 expression, as already 
shown, to postmitotic GCP and not colocalising with the BrdU signal (c). Staining P4 sagittal cerebellar section with 
α−p27 (d) and α-pVHLMm (CT) (e) revealed pVHL expression in the same subset of cells in the EGL as α−p27 (f) as well 
as probably in adult granule cells (higher magnification view seen in g,h and i respectively). Staining sections with the 
Purkinje cell marker α-calbindin (j) and α- pVHLMm (CT) (k) revealed no colocalization to the same cell (l) excluding 
VHL expression in Purkinje cells at this stage. Scale bar represents 50 µm (d-f) and 20 µm (g-l). 
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By marking mitotic cells at P7 in the EGL with BrdU (a) and staining additionally 
with p27 (b) we confirmed the well-documented fact that p27 is expressed in cells that 
have become postmitotic and therefore no colocalization could be seen (c). Staining P4 
sagittal cerebellar section with α−p27 (d,g) and α-pVHL  (CT) (e,h) revealed that pVHL 
seems to be expressed in the same subset of cells in the EGL as p27 (f,i) as well as 
probably in adult granule cells. Staining sections with the Purkinje cell marker α-calbindin 
(j) and α- pVHL  (CT) (k) revealed no colocalization to the same cell (l) excluding VHL 
expression in Purkinje cells at this stage.  
In summary we could show that pVHL expression during cerebellar development 
seems to be localized to a specific subset of granule cell precursors that have exited the cell 
cycle and are about to migrate. Whether Vhl expression persists in the migrating cells will 
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Conditional inactivation of VHL in the 
mouse brain 
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Based on the new finding, that VHL protein expression was strongly detectable during 
cerebellar and retinal development (chapter 8), and on the already proposed role for VHL 
in neuronal differentiation (Kanno et al., 2000), we decided to investigate the role of the VHL 
tumour suppressor gene in neuronal precursor cells in the context of the CNS development.  
In order to do so we took advantage of two already established mouse strains: the 
VHL floxed/floxed (VHLfl/fl) mice (Haase et al., 2001), which we had also tried to create (as 
shown in chapter 7), and transgenic mice that express the Cre recombinase under the 
control of the neuron-specific nestin promoter (nes-Cre) (Tronche et al., 1999). Nestin is an 
intermediate filament protein expressed predominantly in the neural progenitor cells during 
murine CNS development (Lendahl et al., 1990) and in skeletal muscle. But in addition it can 
also be detected in the developing (neuro) retina around E12.5 (Yang et al., 2000). 
The VHLfl/fl mice contain on both alleles a loxP-flanked (floxed) exon 1, whereas 
the nes-Cre mice express Cre under the control of the rat nestin (nes) promoter and 





Figure 44. Structure of the nestin-Cre transgene. Cre recombinase was expressed under the control of the promoter 
and the nervous system-specific enhancer present in the second intron of the rat nestin gene. hGH poly(A), human growth 
hormone polyadenylation signal. 
                                                              From Tronche et al., 1999 
 
Both mice strains had been shown to be viable and healthy and had been previously 
utilized in different conditional knockout experiments (Pfander et al., 2004, Graus-Porta et al., 
2001; Haase et al., 2001, Tronche et al., 1999). In addition, the nes-Cre mice had been 
characterized by crossing them with a reporter mouse line that carries a Rosa26lacZ-loxP 
gene (where lacZ expression is induced by Cre-mediated recombination) showing efficient 
and widespread recombination in precursors of neurons and glia starting around embryonic 
day E 10.5 (Blaess et al., 2004; Graus-Porta et al., 2001).  
 
1) Generation of nes-Cre; VHLflox/flox mutant mice 
 
In a first breeding step VHLfl/fl mice were bred with nes-Cre mice in order to generate nes-
Cre; VHLfl/+ mice (FIG. 45A). These mice were then bred again with VHLfl/fl and the 
offspring screened for the appearance of the nes-Cre; VHLfl/fl genotype (FIG. 45B). This 
genotype was then expected to lead to the excision of the floxed exon 1 of VHL only in 
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tissues where nestin was expressed. The genotype was determined by PCR on tail biopsies 
and the VHL status was assessed in addition by southern blot analysis (data not shown).  
 




to death of newborn pups within a day after birth. The screening of the mice was performed 









F hematic representation of the two breeding steps needed to obtain the nes-Cre; VHL
2) Mice that lack VHL in the nervous system show severe defects in brain    
As expected one out of four pups from a cross between nes-Cre; VHLfl/+ and VHL
45B) had the genotype nes-Cre;VHL  and the deletion of VHL in the nervous system
fl/fl 
nes-Cre mice are heterozygous, therefore the genotype is depicked as tgN (transgene Nestin) / + (for wildtype). By 
crossing a nes-Cre mouse with a VHLfl/fl mouse both nes-Cre; VHLfl/+ and VHLfl/+ mice were born at the expected 
mendelian frequency (1:1). B) By crossing the nes-Cre; VHLfl/+, obtained in the first step, with VHLfl/fl mice the 
conditional VHL knockout nes-Cre;VHLfl/fl was obtained at a ratio of 1:4.  
 
development and die within a few hours after birth 
fl/fl
co Nes co M1 M VHLfl/fl M1 MVHLfl/+
Nestin VHL Figure 46. PCR analysis for VHL and Nestin status of mice. In this example (co) stands for genomic wt DNA, (Nes co)
for a nes-Cre mouse DNA, (M1) was a dying mouse at PO, whereas (M2) was a mouse picked as a control within the same
litter as M1. VHLfl/fl and VHLfl/+ genomic DNA was used as control for the PCR investigating the VHL status. Stars
represent the band of 100 bp for the nestin transgene. Concerning VHL the higher band of ? bp represents the floxed VHL
DNA, whereas the smaller fragment of 500 bp comes from wt DNA. As can be clearly seen M1 is positive for the nestin
transgene and in addition only shows the upper band for VHL, meaning that it is homozygous floxed. The expression of
the transgene in a mouse with a floxed VHL gene leads to conditional inactivation of VHL in neuronal precursors. This
though cannot be monitored by a PCR on tail biopsies, as there nestin will not be expressed.                       88
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To confirm that VHL expression had been really abolished in the brain of conditional 
knockouts, a Western Blot analysis on whole brain extracts was performed utilizing the α-
pVHLMm (CT) antibody, characterized in chapter 8. Different brain regions were in the first 
place examined for their normal VHL expression and were also compared to the VHL 
expression in the cerebellum and the forebrain of two mice which had been shown 
previously by PCR to be nes-Cre;VHLfl/fl (FIG. 47).   
 
Nes-Cre;VHLfl/+ 
     or  VHLfl/fl 
 
Nes-Cre;VHLfl/+















Figure 47. Western Blot analysis assessing pVHL expression in different brain compartments and comparing 
wildtype to mutant brains. 130µg whole cell extract were loaded onto a 12 %-SDS gel and subjected to immunoblotting 
with the α-pVHLMm (CT) polyclonal antibody. The expression of both forms of VHL, pVHL25 and pVHL21, was 
detectable in all brain compartments of mice used as control (Nes-Cre;VHLfl/+,VHLfl/+ and VHLfl/fl) . Overall the 
longer form, pVHL25, seemed to be more abundant than the shorter form, pVHL21. The VHL expression was 
dramatically reduced in parts of brains extracted from nes-Cre; VHLfl/fl mice ( ). A faint band that is still 
detectable for the longer VHL form might arise from contamination from other tissue parts during preparation 
or from the fact that VHL might be expressed in other cell types that are not affected by nestin expression. 
p27-expression was tested as this has been shown to be present in differentiating granular precursors cells 
apparently co-localizing with pVHL expression. But no clear difference in the expression could be detected. 




The expression of VHL was significantly reduced in the cerebellum and the forebrain of 
the two nes-Cre;VHLfl/fl mice tested, leading to the assumption that it was indeed the loss 
of VHL that caused the severe phenotype. 
In order to investigate in more detail the brains of nes-Cre; VHLfl/fl mice whole 
brains were carefully removed from the scull the day of birth (P0) of the animals and the 
appearance of these “mutant” brains was compared to brains at P0 of wild-type C57BL/6, 
nes-Cre;VHLfl/+ and VHLfl/fl mice (FIG. 48). Subsequently the brains were fixed in 10 % 
formalin and embedded in paraffin. 12 µm sections were cut and stained by 
immunofluorescence utilizing the α-pVHLMm (CT) (FIG. 49) the HIF-1α or VEGF 
antibody (data not shown) or by simply staining with hematoxylin and eosin (FIG. 50).  
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When comparing the exterior appearance of 
the PO brains there were no phenotypic abnormalities 
noticeable in the whole structure (FIG. 48). However, 
the brains of nes-Cre;VHLfl/fl mice appeared slightly 
smaller and more vascularized as can be seen in 
figure 48B and 48C. It is nevertheless not clear 
whether this red colour and the vessels were not 
enhanced due to the stress of the death process that 
was ongoing in the moment the animals were 
euthanized 
Before looking at the expression pattern of the 
VHL protein (pVHL) in the mutant brains the VHL 
expression was assessed at P0 (the day of birth) in the 
whole brain in order to obtain a reference. Up to that 
point we had been mainly interested in the cerebellum 
and had not looked at the rest of the brain that much 
and it was therefore very important to define whether 
there was localized expression of VHL in the rest of 
the brain. As shown in figure 49A, VHL expression 
at P0 seems to be ubiquitous in the brain, with 
enhanced staining at the periphery of the 
telencephalon, the hippocampus and the cerebellum 
(marked by arrowheads). There were no differences 
noticeable when comparing wt C57BL/6 brains with 
brains from nes-Cre;VHLfl/+, VHLfl/fl or nes-Cre 
mice (data not shown). But when we compared 
pVHL expression in the brain of mutant nes-
Cre;VHLfl/fl mice to the expression of pVHL in wt 
animals the first striking thing that was noticable 
was actually the severe brain abnormalities that could be seen in the overall structure. In 
addition there was also a strongly reduced VHL expression detectable especially in the 
outer regions of the brain mentioned before (FIG. 49).  
Figure 48. Comparison of wt brains at P0
with the conditional inactivated nes-
Cre;VHLfl/fl mice.  A) The brain of a wt
mouse (or nes-Cre;VHLfl/+, VHLfl/+ or
VHLfl/fl mouse) at PO appears whitish and
some vessels can be distinguished. B) The
brain of a nes-Cre;VHLfl/fl at PO presents
itself as much more red in colour with strong
highlighting of small vessels all over the
brain. Besides the colour and the highlighted
vessels the phenotypic appearance is though
normal. C) When comparing directly a wt
mouse with a nes-Cre;VHLfl/fl mouse  the
only noticeable additional difference, apart
from the colour, is the size that seems to be
slightly reduced in case of the nes-
Cre;VHLfl/fl  mice.   
As all these sites where enhanced VHL expression could be detected are developing 
strongly in the time frame around birth and as loss of VHL had such a severe impact on the 
                      90
                                                                                                                                                         Results Part 3                              
overall brain architecture, VHL seems to play a role somewhere in between the processes 
of proliferation, exit of cell cycle, migration and differentiation as already proposed by the 









Figure 49. Brain section stained with α-pVHLMm (CT). (A) VHL expression, as assessed by immunostaining utilising 
a mVHL-CT polyclonal antibody (see chapter 8), seems to be ubiquitous in wt mice at birth (PO). One can notice a strong 
expression of VHL on the outer borders of the cerebral and the cerebellar cortex (shown by arrows). B) The comparison 
of the brain at P0 of a nes-Cre;VHLfl/fl mouse with the wt brain depicted in A first of all shows much weaker overall VHL 
staining suggesting that the conditional inactivation of VHL has functioned properly. The signal was not expected to be 
lost completely as not all cell types are targeted by this conditional inactivation and there will still be residual VHL 
expression in these non-targeted cells or vessels. The two arrows point at the corresponding places in A) showing clearly 
that the brain development is somehow impaired in these mice leading in addition to open spaces within the brain.  
 
In order to investigate in more detail the effect of VHL loss in the brain we focused 
on the telencephalon and the cerebellum. As seen in figure 50 the telencephalon of mutant 
nes-Cre;VHLfl/flmice (FIG. 50B) showed big holes which are ofter referred to in the 
literature as hydrocephalus, empty spaces probably filled by cerebrospinal fluid that upon 
fixation gets lost and appears as empty holes. In addition the outer layers seem to be 
thinner as in the wt control. Comparing the cerebella gives a similar picture: in the mutant 
mouse the cerebellum (FIG. 50D) seems to form but is perturbed and the surroundings 




Figure 50. Hematoxylin and 
Eosin stainings of sagittal 
sections of the nes-Cre;VHLfl/fl 
brains in comparison to their wt 
control. A) and B) respresent a 
picture of the telencephalon with 
the hippocampal structure while 
C) and D) show the cerebellum 
and its surrounding. A) and C) are 
wt control whereas B) and D) 
represent a nes-Cre;VHLfl/fl brain.  
When comparing the 
telencephalons in A) and B) the 
difference is striking, showing that 
in the mutated brain the overall 
structure is perturbed and  the 
same grade of perturbation can be 
seen also in the cerebellum. 
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3) Mice that lack VHL in the nervous system show a possible effect in the 
retina 
 
As we had investigated VHL expression in the retina as well as in the cerebellum as part of 
this thesis it would have been interesting to specifically delete VHL in these cells. 
Unfortunately though due to the lack of a Mueller glia cell specific Cre-mouse we didn’t 
have the chance to knock out VHL specifically in these cells. However, it was surprising to 
find that in one of the examined nes-Cre;VHLfl/flmice when we looked at the retina a 
strange involution could be noted that in addition stained positive for VHL. Now, it is 
known that Nestin is expressed specifically at E 12.5 in a part of the neuroretina, so it could 
be an effect of the deletion of VHL in the precursor cells. But this will have to be 
investigated further and will also need to be seen reproducibly. Nevertheless it is an 















staining of wt and
mutant retinae.  A) and
B) represent a wt retina
whereas C) and D)
represent a mutant retina.
A) and C) show
Hematoxylin/Eosin 
stainings, while B) and
D) depict pVHL
expression as assessed by
immunostaining with the
α-pVHLMm (CT)
antibody. In the mutant
brain an involution of the
neuroretina can be seen




In conclusion VHL seems to play a specific role during the development of the 
brain as loss of VHL, mimicked by a mouse model in which VHL was deleted specifically 
in neural precursor cells, leads to a severe brain phenotype and results ultimately in the 
death of newborns. 
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Chapter 10 
 
Discussion and future perspectives 
 
The most common lesions found in VHL disease include hemangioblastomas, which are 
neoplasms containing a mural nodule formed by noninvasive, vacuolated “stromal” cells of 
unknown origin that are embedded in a network of capillaries. VHL disease-associated 
hemangioblastomas can be found mainly in the retina and the cerebellum. Both lesions 
exhibit indistinguishable histological characteristics, with VHL loss restricted to stromal 
cells, suggesting that this is the neoplastic component.  Given the central role of VHL in 
hypoxia signaling through regulation of HIF, these tumors consequently provide an in vivo 
view of HIF effects in a tumor.   
Multiple mRNA expression studies, aiming at investigating VHL expression in 
tissues, have documented that VHL mRNA is present ubiquitously and not restricted only 
to tissues affected during the course of VHL disease. In addition immunolocalization 
studies utilizing poly- and mono-clonal VHL antibodies recognizing human pVHL 
additionally proved that the protein expression is not restricted to specific tissues either but 
can be found widespread, particularly within epithelial cells.  
Although these studies provided an insight into pVHL expression in adult human 
tissues, so far no studies have addressed the issue of elucidating the VHL protein 
expression pattern and therefore its function during development. In addition, in-depth 
analysis of pVHL expression focusing in tissue-specific cell types e.g. in the retina was still 
pending. Knowing the identity of the cell that expresses VHL, and that is therefore prone to 
unforeseen misregulation by VHL loss, would definitely provide a better target for 
additional studies investigating cures or remedies for the disease. 
To gain more insight into pVHL expression we decided to focus on two tissues that 
are heavily affected during the course of VHL disease, namely the retina and the 
cerebellum. We investigated the VHL protein expression in these two murine tissues 
during development and adulthood by immunostaining utilizing a newly characterized 
antibody that specifically recognizes murine pVHL. 
pVhl expression in the retina was found throughout development. In addition, it was 
localized exclusively to a very specific cell type, the Müller glial cell, towards the end of 
development and in adulthood. As the so-called “stromal” cells in hemangioblastomas have 
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been hypothesized to be of glial cell origin, due to ultrastructural and 
immunohistochemical features (Lubinski et al., 2003), the discovery that under normal 
conditions pVHL is expressed in the principal glial cell of the retina is striking. 
Overall the finding that pVHL is expressed in retinal precursor cells and that its 
expression is unique to Müller glial cells in adult mice proves to be interesting for a variety 
of reasons:  
First, the observed temporal expression pattern would suggest that VHL has some 
function during development, maybe even in directing glia differentiation. It has been 
shown that VHL plays a role in neuronal differentiation in the CNS (Murata et al., 2002; Kanno 
et al., 2000), but in these studies it was not linked to glial histogenesis. The finding that VHL 
expression is prominent in glial cells in the retina is though not really in contrast to these 
results in the CNS, because one has to keep in mind that VHL is already expressed 
throughout the retinal development in precursor cells, which are multipotent giving rise 
both to all the neurons and the glial cell type.  Moreover it is likely that VHL anyway 
exerts different functions in different cell types.  
The homeobox gene Chx10 has been shown to be expressed during development in 
most proliferating retinal cells. As cells exit the cell cycle, they downregulate Chx10 
expression and shortly thereafter differentiating bipolar cells up-regulate and continue to 
express this protein again (Cunningham et al., 2002). However, as a detailed analysis of the 
timing of the expression of Chx10 during cell cycle has not been carried out, it is thus not 
known whether Chx10 expression persists in a subset of retinal progenitor cells as they exit 
the cell cycle or if postmitotic neurons committed to becoming bipolar cells reinitiate 
expression as they differentiate. VHL follows a similar pattern of expression but being 
finally unique to the Müller glial cells. The expression of pVHL didn’t seem to be always 
equally strong in retinal precursor cells as e.g. especially after/ around birth the signal 
intensity seemed to decrease (data not shown) and this time span is the one in which Müller 
glial cells are born together with bipolar cells and rods. It will be therefore interesting to 
have a closer look as to whether this phenomenon of signal reduction is reproducible. In 
addition by retroviral-mediated overexpression of VHL (coexpressed e.g. with GFP) in 
mitotic retinal progenitor cells one could monitor whether more cells become Müller glial 
cells. This would then confirm that VHL provides or relays a signal needed for 
specification to this cell type. When trying to unravel VHL function in this setting it will be 
necessary to find out which biological process is affected by VHL the most among 
proliferation (cell division/ multiplication), differentiation (into specialized retinal cell 
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types), and apoptosis (programmed cell death). Interestingly in the elegant survey focusing 
on the genomic analysis of mouse retinal development by serial analysis of gene expression 
(SAGE) VHL was not identified (Blackshaw et al., 2004). However, in the same report they 
showed that mitotic retinal progenitor cells and Müller glia share a great degree of 
transcriptional overlap. Of the genes being specifically expressed in MG during the first 
postnatal week 68 % were found to be also enriched in mitotic progenitor cells. These two 
cell types resemble each other morphologically and based on the extensive overlap in gene 
expression it is interesting to speculate to which degree they also share a functional 
similarity. Müller glia are one of the last cell types to exit mitosis (Reh and Levine, 1998) and 
they are the only cell type in the mature retina that can reenter mitosis following retinal 
injury (Dyer and Cepko, 2000; Vetter and Moore, 2001). Moreover, data from chicken suggest that 
Müller glia can be induced to divide and give rise to some types of retinal neurons for a 
short period of time near the end of retinal development (Fischer & Reh, 2001). All these facts 
actually lead to the interesting, even more challenging question as to whether Müller glia 
are fundamentally multipotent progenitor cells that are simply quiescent regarding cell 
division and the production of neurons.  Given the well-documented role of VHL in the 
control of gene expression primarily through HIF regulation and potentially other effectors, 
and the coupling of glial cell fate with specific gene expression patterns, it would be of 
interest to investigate the contribution of VHL-mediated gene expression in these 
processes. 
 Second, the fact that VHL is expressed solely in the Müller glial cells provides a 
model cell type in which to further analyze VHL function. Hypoxia has been shown to 
induce VEGF and TGF-β expression of Müller glial cells leading to neovascularization 
fitting therefore to the current knowledge about VHL: both VEGF and TGF-β are HIF 
target genes and HIF is active under hypoxia but normally degraded by VHL under 
normoxia. Interestingly it has been shown that p27 expression, which has been postulated 
to be linked to VHL expression by a yet unknown mechanism, is also restricted to the 
nucleus of müller glial cells in the adult retina. In addition, the fact that Mueller glia play a 
major role in every single disease or injury associated with the retina by initiating a process 
called reactive gliosis calls for further investigations of VHL expression in this context. 
Müller cell gliosis is characterized by a downregulation of p27 levels, by proliferation, 
changes in cell shape due to alterations in intermediate filament production and by 
secretion of signaling molecules such as VEGF, promoting neovascularisation in the 
surroundings. This setting now provides a great model system to unravel the role that VHL 
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plays in the retina. Our next aim is to further investigate whether reactive gliosis has an 
effect on VHL expression. This process can be induced by intraocular injections of ouabain 
utilizing subsequently immunostaining to monitor the changes in expression levels (Dyer & 
Cepko, 2000). It will be exciting to see whether the VHL pathway is downregulated in these 
cases because if this were the case one could envision a model of how actually 
hemangioblastomas could arise: Changes in the cellular redox status and the production of 
reactive oxygen species are associated with retinal injury. Under such conditions, it is 
likely that downstream VHL effectors are differentially modified thus evading destruction 
by the E3 ligase function of the protein. Such downregulation of the VHL pathway during 
the process of reactive gliosis would probably create a condition similar to that encountered 
in case of VHL loss due to mutation. The Müller glial cells would start proliferating again, 
probably expressing glial markers at the beginning, but then switching more to precursor 
markers again (that would explain the fact that there are controversial data regarding the 
markers expressed by stromal cells) and neovascularization would occur due e.g. to the 
expression of VEGF. Whether in reality it is as simple as this model would suggest the near 
future will tell.  
 
As opposed to the retina, in the cerebellum we could show that pVHL expression 
seems to be localized to a specific subset of cells during development, whereas in 
adulthood the expression appeared more ubiquitously and overall reduced. Localizing 
pVHL expression to the non-proliferating subset of granule cell precursors is in complete 
accordance to an already proposed function of VHL in neuronal differentiation and is 
therefore not surprising. In addition some facts even further encourage the idea of a 
specific role played by VHL in these cells at that particular stage:  
1) p27 expression has been shown to be high in GCP cells that have exited the cell cycle 
(Miyazawa et al., 2000). Based on a proposed link between VHL and the cell cycle it is 
interesting to see that both in the retina and in the cerebellum VHL and p27 seem to be 
expressed in the same subset of cells. Whether this correlation translates into a true link at 
the molecular level needs further investigation. With regards to this, we are currently 
crossing floxed VHL mice with p27-/- mice to then delete VHL specifically in the brain by 
using again the Nestin-Cre mice discussed further down. As p27-/- mice have been shown 
to have enlarged organs (Fero et al., 1996) including a larger cerebellum (Miyazawa et al., 2000), it 
will be interesting to see whether knocking out VHL specifically in the brain reverts this 
phenotype or not.  
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2) expression of Cyclin D1 (or the brain-specific cyclin D2), which has been shown to be 
negatively regulated by VHL (Bindra et al., 2002; Zatyka et al., 2002), drops in postmitotic 
granule cell precursors.  
3) CXCR4 expression, which is regulated by HIF that in turn is regulated by VHL (Staller et 
al., 2003), has been shown to be present in proliferating granule cell precursors where it 
plays a role together with its ligand SDF1 (expressed from pial cells) to enhance the SHH-
induced proliferation of granule cell precursors (Lewis et al., 2004; Dahmane & Altaba, 1999). 
CXCR4 mRNA expression peaks in the first two postnatal weeks and from localization 
studies it seems that CXCR4 protein is localized only to the outer part of the EGL and not 
in the VHL expressing postmitotic GCPs. All these facts sustain a possible role for VHL in 
these precursor cells, due to the fact that it should not be possible for VHL and CXCR-4 to 
be expressed in the same cell type assuming that for CXCR4 expression on the membrane, 
HIF needs to be present and active. Maybe absence of CXCR4 expression due to the 
presence of VHL could even lead to the start of differentiation of granule cells (if the 
proliferation-driving signal provided by SHH is not sufficient). 
 
The possible role of VHL played during differentiation in the cerebellum though, does still 
not explain what could happen in an adult cerebellum when lower VHL expression occurs.  
In conclusion of the expression studies, the observed VHL expression during retinal 
and cerebellar development substantiates a previously suggested role of VHL in 
differentiation. The fact that VHL seems to be localized to glial cells in the retina while 
being present in neuronal cells is not in contrast as we could show that VHL is present 
throughout the retinal genesis in the precursor cells which are multipotent and can therefore 
generate glia and neuronal cells. In accordance to this, it is assumed that VHL exerts 
different functions in different tissues. This must be the case as it would be otherwise not 
explicable why despite widespread VHL expression only a small subset of organs are 
affected during the course of VHL disease. This assumption is further substantiated by the 
newly ascribed function of microtubule stabilisation to VHL (Hergovich et al., 2003) which, 
however, despite the implications for a disease-type specific connection to particular VHL 
functions, is still pending evidence for a physiological role in vivo. Finally, the 
identification of Müller glia as the primary Vhl-expressing cell type in the adult retina 
provides a firm basis for the elucidation of the pathophysiological and molecular 
mechanisms that give rise to the observed VHL disease phenotypes.  
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A part of this thesis was dedicated to the creation of a conditional VHL knockout mouse 
model. The aim was to create a floxed VHL mouse, where exon 1 of the VHL gene would 
have been flanked by two loxP elements. This would have then allowed, by crossing these 
animals with cre-expressing mice, an excision of exon 1 leading therefore to the loss of 
VHL in the cre-expressing tissues. When this project was initiated in the year 2000 the only 
published report concerning a mouse model for VHL disease was the complete knockout 
that led to the death of the pups very early in gestation. Due to the lack of possibility to 
study VHL function more extensively in these mice the creation of floxed mice would have 
been a major achievement. During the course of this knockout project a conditional VHL 
knockout was though published by another laboratory (Haase et al., 2001). Although this was 
a major adversity at that time, we decided nevertheless to continue in our intent because of 
the following: The complete knockout published by Gnarra in 1997 had shown that 
homozygous deletion of VHL in C57BL/6 mice led to vascular abnormalities in the 
placenta leading to the death of the embryos at 10-12.5 days of gestation. The conditional 
knockout published by Haase inactivated VHL in BALB/c mice. Comparing the 
heterozygous VHL mice showed that while the heterozygous VHL C57BL/6 mice didn’t 
show any phenotype, heterozygous VHL mice on a BALB/c background developed hepatic 
hemangiomas. Reports in the literature have suggested that mouse models for human 
disease may develop variable phenotypes depending on the strain background, possibly due 
to the presence of polymorphic variants in certain modifier genes in some strain. As a 
recent example: the creation of a VHL conditional knockout mouse model on a C57BL/6 
background was described which developed liver angiomas in 100% of animals within one 
year (Ma et al., 2003). When this phenotype development was compared in different strains 
by introducing the VHL deleted allele also in BALB/c and A/J mouse strains a remarkable 
increase in development of hepatic vascular lesions was observed. Coming back to our 
original aim, we wanted to create a conditional knockout in the C57BL/6 background. 
Unfortunately though it proved to be impossible maybe due to unforeseen recombination 
events happening in the clones or due to adverse culturing conditions. It is also possible 
that the clone 117, which we picked for the second transfection, had a wild-type ES-cell 
contamination. However, at that point, given the availability of floxed VHL mice, we 
decided to use the information gained by our expression studies in the cerebellum to 
investigate the function of VHL in the central nervous system (No Müller glial cell specific 
Cre-strain exists so far). In order to do so a conditional knockout mouse was generated with 
the Cre/loxP system utilizing a nestin promoter-based neural precursor-specific Cre 
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recombinase. The thesis presented  herein documents that neural cell-specific ablation of 
the VHL gene in mice leads to severe brain structure abnormalities resulting in premature 
death occurring shortly after birth. These are preliminary data from an ongoing study that 
needs further investigation as to HIF-1α- or related target genes expression levels either by 
immunostaining or by RT-PCR. Interestingly, in knockout animals of Hif-1α, which has 
been shown to be expressed in the brain, a brain phenotype was also encountered that 
resembles the one we found (Tomita et al., 2003; Jain et al., 1998; Ryan et al., 1998). This 
phenotype is defined as hydrocephalus, the term coming from the greek words ‘hydro’ 
meaning water and ‘cephalus’ meaning head. The hydrocephalus is an abnormal build-up 
of cerebrospinal fluid in the brain. In sections it is recognizable by empty spaces as the one 
noticeable in figure 50. Based on our current knowledge VHL and HIF protein expression 
should be mutually exclusive. Furthermore, it is more and more appreciated that oxygen 
may act as a morphogen in neural tissues in that localised fluctuations in oxygen levels 
drive specific transcriptional programs (Acker & Acker, 2004; Sharp & Bernaudin, 2004). Given 
the similarities in the phenotypes of the two knock-out mice one could envision that 
differential VHL expression in the brain may create an antagonistic environment between 
high and low VHL-expressing cells, with varying responsiveness to surrounding oxygen 
levels and as such comprising a driving force in the differentiation of these brain 
compartments.  
  In addition the layers of the telencephalon in the VHL knockout mouse seemed to 
be smaller in size leading to the assumption of a probable effect of VHL on cell 
proliferation. In this case this would mean that VHL actually promotes proliferation. And 
therefore this finding would add up to the accumulating contrasting reports evaluating the 
effect of VHL on the cell cycle (see also the latest mouse model where VHL was knocked 
out in all cartilaginous elements to investigate its role in endochondral bone development 
(Pfander et al., 2004). Given that these observations are still at a preliminary stage of 
investigation it would be premature to provide a definite answer as to which effect VHL 
exerts but our ongoing studies of the observed severe brain phenotype are warranted to 
elucidate novel functions associated with this interesting tumour suppressor. 
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